Introduction {#S1}
============

Specific regulatory requirements for carcinogenicity assessment of new pharmaceuticals are described in International Conference (now Council) on Harmonisation (ICH) guidance documents, i.e., ICH Guidelines M3(R2) ([@B1]), S1A ([@B2]), S1B ([@B3]), S1C(R2) ([@B4]), S2 ([@B5]), and S6(R1) ([@B6]).

Carcinogenicity studies are generally required for new pharmaceuticals that would be administered for 6 months or longer, or in a frequent and intermittent manner. In general, a 2-year rat study, plus either an 18 (or 24)-month mouse study or an alternative 6- or 9-month study in transgenic mice, is requested for such compounds.

The current 2-year rodent carcinogenicity study design used since the mid-1960s has been the regulatory standard in the safety assessment of humans. These carcinogenicity studies are expensive and time-consuming animal tests required for the safety assessment of pharmaceutical compounds. However, there is considerable scientific doubt about the reliability of the rat bioassay. Too many compounds are positively enhancing a tumor response in these studies, which may simply be due to the long-term exposure of the animals to rather high doses of the test compound ([@B7]--[@B9]) rather than a true carcinogenic effect. Therefore, there is a continued and increasingly need to justify the 2-year rodent bioassay in an attempt to reduce animal numbers, time, and costs ([@B10], [@B11]). For this reason, pharmaceutical companies and regulatory bodies are aiming to find an alternative approach.

In light of concerns raised about the predictability of *in vivo* studies in general and the push for refinement, reduction, and replacement of animal studies, it is strongly recommended to re-evaluate the suitability of the 2-year rodent bioassay as the best approach to predict human disease ([@B12]--[@B21]).

We have undertaken a retrospective study of pharmaceuticals with available rodent subchronic (3- to 6-month studies) and carcinogenicity data to test the hypothesis that it is possible to replace the current 2-year bioassay with a weight-of-evidence approach, i.e., by using evidence from all the non-clinical data available at the stage of development of a compound, usually at the end of Clinical Phase II, when a decision for conducting a 2-year carcinogenicity study is usually taken. Data that contribute are the results of the subchronic toxicity studies, in combination with genotoxicity data and knowledge of pharmacodynamic properties relating to the mode of action.

Positive *in vivo* genotoxicity tests are generally considered as indicative for a carcinogenic potency of a compound. Under REACH ([@B22]), classification as a mutagen category 1A or 1B allows a waiving of the carcinogenicity study, since the default presumption is that a genotoxic mechanism for carcinogenicity is likely. The same is true for human pharmaceuticals, where the ICH S1A guideline indicates that in case of positive genotoxicity, no lifetime carcinogenicity studies are expected. Positivity in an assay for DNA reactivity will usually also preclude further development ([@B23]), unless the risk for genotoxicity is acceptable in view of the benefit of the compound.

Jacobs ([@B24]) examined the data from 13-week rat toxicity studies for the prediction of carcinogenicity outcome using 60 pharmaceutical compounds. The data were obtained from a USA Food and Drug Administration (FDA) database. She concluded that various short-term indicators of carcinogenicity, such as hyperplasia, hypertrophy, greater organ weight, tissue degeneration or atrophy, and mineralization in a tissue, did not always result in tumors in that tissue, although (some of) these indicators are considered signs of potential carcinogenicity. The tissues examined were limited to the liver, kidneys, mammary glands, adrenals, urinary bladder, and lung.

Reddy et al. ([@B25]) confirmed the conclusion of Jacobs ([@B24]) with a different dataset. They used a "whole animal response" instead of individual tissues, testing the hypothesis that evidence of absence of putative preneoplastic lesions in any tissue may accurately predict a compound's lack of carcinogenic potential. In their view, the presence of treatment-related putative preneoplastic histopathological lesions is not a definitive indicator of a tumorigenic potential of a compound, but rather requires that a 24-month rat carcinogenicity study has to be run and all tissues and organs should be collected and examined.

Sistare et al. ([@B16]) further evaluated the predictivity of histopathological findings, considering risk factors for rat neoplasia (hypertrophy, hyperplasia, metaplasia, cell proliferation, foci of cellular alteration, and inflammation accompanied by recurrent cell necrosis and repair) that were observed microscopically in 6-month rat toxicity studies with the tumor outcomes in rat 2-year carcinogenicity studies for 182 pharmaceuticals derived from 13 pharmaceutical companies. They concluded that the absence, rather than the presence, of the aforementioned putative preneoplastic histopathological changes in rats was a reliable predictor of tumor outcome in the corresponding tissue. The authors proposed that compounds demonstrating no genotoxicity, no evidence for hormonal mechanisms, and no histopathological changes pointing to a risk factor for rat neoplasia in any tissue (called NEGCARC approach) are considered rat non-carcinogens and can be exempted from the requirement for testing in a 2-year carcinogenicity study.

Assessors from EU Regulatory Authorities on human pharmaceuticals started to evaluate this approach and this set of data by emphasizing the consideration of the pharmacological properties of each compound and relating these properties to the outcome of the rat carcinogenicity study. The dataset was extended with data from FDA and the Japanese Pharmaceutical Manufacturer's Association, increasing the number of compounds to 255 ([@B26]). Pharmacological properties appeared to be well associated with the outcome of the rat carcinogenicity study, both in a positive and negative direction. Classes such as β~2~-agonists and dopamine D~2~ antagonists were rather strongly associated with induction of mesovarian leiomyoma and mammary gland tumors, respectively ([@B26]). In addition, compounds inducing liver-associated pathology appear to be important in predicting tumors in organs such as liver, thyroid, and testis. The enzymes responsible for metabolism are also important factors in this respect.

The present retrospective study is intended to gather information independently from the dataset of Sistare et al. ([@B16]) to further test the hypothesis that a weight-of-evidence approach is possible in predicting the carcinogenic potential of human pharmaceuticals based upon histopathological and pharmacological properties. We have used a more restrictive approach in the definition of putative preneoplastic changes as compared with Sistare et al. ([@B16]), which will be further discussed below.

Materials and Methods {#S2}
=====================

Selection of Compounds {#S2-1}
----------------------

The rat subchronic toxicity and chronic carcinogenicity data used for this evaluation came from the assessment reports that are available at the Medicines Evaluation Board of the Netherlands. The compounds and studies that were included were those in the paper of Van Oosterhout et al. ([@B27]), which reviewed all of the carcinogenicity studies from 1979 when GLP was introduced, although it was not possible to retrieve all of the studies covered in that paper, those submitted for marketing authorization in the Netherlands between 1995 and 2004, and those authorized *via* the EU centralized procedures between 2004 and 2014. The criteria used to identify valid pairs of rat subchronic (3- and/or 6-month) studies and 2-year carcinogenicity studies were as described below.

ToxRefDB Database Structure {#S2-2}
---------------------------

We have downloaded an empty version of ToxRefDB from the website of the US Environment Protection Agency (EPA), and we have used the structured organization to summarize all the data available for the carcinogenicity studies. We started our assessment based on the assessment report, but in cases where there was a lack of detail, we used the non-clinical expert report, non-clinical overview, or other parts from the dossier available on microfilm or electronically.

Comparison of Protocols of Subchronic Studies with Carcinogenicity Studies {#S2-3}
--------------------------------------------------------------------------

Although similar criteria regarding overlap of dose range have been applied as previously reported by Reddy et al. ([@B25]) and Sistare et al. ([@B16]) for inclusion of the studies, we have included all compound datasets available, as the impact of the pharmacological properties is expected to be largely independent of the matching of doses.

The database contained the dose levels used in the subchronic and carcinogenicity studies and the effects of the pharmaceuticals on body weight, organ weight, histopathology of a large set of organs and tissues, and results of genotoxicity tests *in vitro* and *in vivo*.

Criteria for Positive Genotoxicity Test Result {#S3}
==============================================

Genotoxicity is usually tested with a battery of genotoxicity assays, as detailed in the ICH guidelines S2A and 2B revised in S2R2 ([@B5]). The outcome of these tests was taken from the assessment reports and was not re-assessed.

Compounds Classification and Description of Study Outcomes {#S4}
==========================================================

The pharmaceuticals were classified for pharmacology, and subsequently, the histopathological outcome of the studies has been described. The results of genotoxicity studies were included to cover similar criteria as used by Sistare et al. ([@B16]).

Pharmacological Criteria {#S4-1}
------------------------

The pharmacotherapeutic areas were based on target organs, such as central nervous system (CNS), cardiovascular system (CVS), respiratory system (RS), metabolic system (MB), hormonal system (HM), gastrointestinal system (GIS), immunological system (IS), and antimicrobials (AM) (divided into antibacterials, antimalarials, antivirals, antifungals, and remaining compounds). Each pharmacotherapeutic category was subdivided into classes according to the primary drug target of the compounds in accordance with Stefansdottir et al. ([@B28]). Small molecules may exert additional pharmacological activity at a higher dose, which is termed secondary pharmacodynamics and could, as described by Keiser et al. ([@B29]), be responsible for the carcinogenic response.

Histopathological Criteria {#S4-2}
--------------------------

Positive histopathology observations were scored if any of the selected histopathological changes were reported as being increased in the subchronic toxicity studies, i.e., cellular hypertrophy, cellular hyperplasia, presence of altered hyperplastic foci of cellular alteration (atypical) cell foci (basophilic; acidophilic foci), cellular proliferation, and dysplasia. Furthermore, any changes in body weights and organ weights changes were noted.

The compounds were scored as negative for histopathological evidence of potential preneoplasia when the aforementioned histopathological changes were absent or not considered as being increased by treatment. All incidences reported to be higher than the controls were considered positive; with no access to all of the original study reports, no attempts were made to re-evaluate them in terms of whether or not they were statistically significant. When the histopathological changes were incorporated in the database, they were considered to be related to treatment and significantly increased.

We have scored greater organ weights, hypertrophy, and hyperplastic findings separately in Table [1](#T1){ref-type="table"}. Furthermore, we have listed the tumors observed by describing the organ system and the histopathological appearance.

###### 

**Summary of the observations in the subchronic and carcinogenicity studies**.

  \#    Mode of action                                    Cat His   Cat Ph.                               Fin Cat.   Weight                                               Subchronic           Carcinogenicity   
  ----- ------------------------------------------------- --------- ------------------------------------- ---------- ---------------------------------------------------- -------------------- ----------------- --------------------------------------------------------------
  231   AB, fluoroquinolone                               FN        NT                                    FN         col; kid                                             --                   --                hsyst leu
  244   AB, fluoroquinolone                               FN        NT                                    FN         --                                                   --                   --                pan tu
  263   AB, fluoroquinolone                               FN        NT                                    FN         ce; hrt; li; spl; adr; ova                           --                   --                kid ac
  226   AF, conazole derivative                           FN        NT                                    FN         li                                                   li                   --                li ad
  236   AF, conazole derivative                           FN        NT                                    FN         adr; li; hrt; kid; thy; lu; spl; pan; br; gon; ova   adr                  --                soft t sar
  279   AF, remaining, allylamine derivative              FN        NT                                    FN         hrt; adr                                             --                   --                tes tu; li ad; li ac
  246   AV, CCR5 receptor antagonist                      FN        NT                                    FN         --                                                   thyr                 --                thyr ad
  218   AV, hepatitis B-inhibitor                         FN        NT                                    FN         --                                                   --                   --                pan ad; pan ac; li ad; li ac; zymgl ca; br gli
  220   CNS, 5HT~2~ antagonist                            FN        NC                                    FN         --                                                   --                   --                li ad
  230   CNS, remaining, α~2~-delta agonist                FN        NC                                    FN         --                                                   --                   --                pan ac; pan ad; tes ad; ut polyp
  251   CNS, remaining, antidepressant                    FN        NC                                    FN         --                                                   li; thyr             --                thyr ac; mam ca; li ad; li ac
  217   CNS, remaining, COMT-inhibitor                    FN        NC                                    FN         adr                                                  --                   --                kid ad; kid ac
  229   CVS, loop diuretic                                FN        NC                                    FN         --                                                   --                   --                thyr ad; pit ad
  253   CVS, loop diuretic                                FN        NC                                    FN         --                                                   --                   --                tes ad; ut ac
  284   CVS, loop diuretic                                FN        NC                                    FN         --                                                   --                   --                kid ac; kid ad
  282   CVS, platelet aggregation inhibitor               FN        NC                                    FN         --                                                   li                   --                thyr ad; adr bpha; ut ac; li ad; ova ad; mam ad
  242   IS, remaining, imidazothiazole derivative         FN        NC                                    FN         --                                                   --                   --                pit ad
  206   AI, COX2 inhibitor                                FN        TN                                    TN         li                                                   --                   --                li ac
  222   AI, COX2 inhibitor                                FN        TN                                    TN         --                                                   li; thyr             --                thyr ad; li ad
  260   AI, NSAID                                         FN        TN                                    TN         --                                                   --                   --                tes ad;
  234   BM, remaining, isoflavone                         FN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                pit ad; li ad
  277   CNS, 5-HT~1b/d~ agonist                           FN        TN                                    TN         --                                                   --                   --                adr bpha; tes ad
  239   CNS, antiepileptic, Na-channel blocker            FN        TN                                    TN         adr; pit; kid; li                                    --                   --                adr bpha
  204   CNS, benzodiazepine                               FN        TN                                    TN         --                                                   --                   --                thyr ad; thym lymph; ut schwan
  248   CNS, benzodiazepine                               FN        TN                                    TN         --                                                   li                   --                thyr ad
  205   CNS, opioid, μ-agonist                            FN        TN                                    TN         --                                                   --                   --                tes tu; hsyst leu
  197   CNS, remaining, melatonin receptor agonist        FN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                li ad; li ac
  223   CNS, remaining, NMDA-antagonist                   FN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                tes ad
  261   CNS, remaining, nootropic drug                    FN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                adr bpha
  250   CNS, SNRI                                         FN        TN                                    TN         --                                                   li                   --                thyr ad
  276   CNS, SNRI                                         FN        TN                                    TN         kid                                                  --                   --                tes ad
  262   CNS, SSRI                                         FN        TN                                    TN         li                                                   --                   --                ln lymph
  208   CVS, ACE inhibitor                                FN        TN                                    TN         kid; li                                              kid                  --                tes tu
  266   CVS, ACE inhibitor                                FN        TN                                    TN         --                                                   --                   --                thyr ac
  271   CVS, ACE inhibitor                                FN        TN                                    TN         --                                                   --                   --                kid ad
  285   CVS, ACE inhibitor                                FN        TN                                    TN         --                                                   --                   --                mam fad
  233   CVS, ACE inhibitor                                FN        TN                                    TN         kid                                                  --                   --                thyr ad; ut polyp
  249   CVS, α~1~ agonist                                 FN        TN                                    TN         --                                                   --                   --                tes ad
  289   CVS, anticoagulant                                FN        TN                                    TN         --                                                   --                   --                pan ad/ca
  203   CVS, β antagonist                                 FN        TN                                    TN         tes; adr; li                                         --                   --                pit tu
  219   CVS, β antagonist                                 FN        TN                                    TN         kid                                                  --                   --                skin SCP
  243   CVS, β antagonist                                 FN        TN                                    TN         thyr; li; adr; kid                                   --                   --                li ad
  255   CVS, β antagonist,                                FN        TN                                    TN         --                                                   --                   --                spl bhaem
  200   CVS, calcium antagonist                           FN        TN                                    TN         --                                                   --                   --                ut polyp
  235   CVS, calcium antagonist                           FN        TN                                    TN         --                                                   --                   --                tes ad
  237   CVS, calcium antagonist                           FN        TN                                    TN         ova                                                  --                   --                tes ad
  240   CVS, calcium antagonist                           FN        TN                                    TN         --                                                   adr                  --                mam fad; pit ad
  256   CVS, calcium antagonist                           FN        TN                                    TN         --                                                   --                   --                thyr ad; thyr ac
  247   CVS, calcium antagonist.                          FN        TN                                    TN         li; hrt                                              --                   --                ut polyp; oral SCC
  252   CVS, imidazoline agonist                          FN        TN                                    TN         --                                                   --                   --                adr tu
  272   CVS, Na-channel block                             FN        TN                                    TN         --                                                   li                   --                thyr ad; tes ad; adr bpha; adr bpha
  209   CVS, PDE3 inhibitor                               FN        TN                                    TN         li; kid                                              --                   --                adr bpha
  232   CVS, remaining, D~1~/α agonist                    FN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         adr; kid                                             --                   --                pan ad
  216   CVS, remaining, imidazole, PDE-inh                FN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                adr bpha
  225   CVS, remaining, quinolone vasodilator             FN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         li; thyr; adr; spl; pros; tes                        --                   --                adr bpha
  198   CVS, remaining, renin inhibitor                   FN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   col                  --                col ad; col ac
  212   GI, 5HT4 agonist                                  FN        TN                                    TN         --                                                   --                   --                tes tu; pit ad
  269   GI, 5HT4 agonist                                  FN        TN                                    TN         --                                                   --                   --                thyr ad; mam fad; pan ad; adr bpha; li ad; pit ad
  210   GI, histamine H~2~ antagonist                     FN        TN                                    TN         li                                                   --                   --                tes ad
  275   GI, histamine H~2~ antagonist                     FN        TN                                    TN         --                                                   --                   --                skin fibr
  238   GI, remaining, sugar alcohol                      FN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   li                   --                tes tu
  194   MB, antidiabetic, α-glucosidase inhibitor         FN        TN                                    TN         --                                                   --                   --                tes ad; kid ad; kid ac
  195   RS, histamine H~1~ antagonist                     FN        TN                                    TN         li; kid                                              --                   --                adr bpha
  207   RS, histamine H~1~ antagonist                     FN        TN                                    TN         --                                                   li                   --                thyr ad; pit ac; li ac
  264   RS, remaining, methylxanthine-derivate            FN        TN                                    TN         li                                                   --                   --                tes tu; mam fad
  268   UB, anticholinergic                               FN        TN                                    TN         --                                                   li                   --                ut polyp; kid pap
  283   UB, anticholinergic                               FN        TN                                    TN         --                                                   --                   --                kid sar
  287   UB, anticholinergic                               FN        TN                                    TN         --                                                   --                   --                skin sar
  196   ZZ, remaining, retinoid, topical, keratinocyte    FN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         pit; adr                                             --                   --                adr bpha; thyr ad
  274   CNS, DA~2~ agonist                                FN        TP                                    TP         adr                                                  li                   --                tes ad; skin fibr
  245   CNS, DA~2~ agonist                                FN        TP                                    TP         --                                                   --                   --                tes ad; tes ca
  265   CNS, DA~2~ agonist                                FN        TP                                    TP         --                                                   --                   --                pit ad; ut ac
  270   CNS, DA~2~ agonist                                FN        TP                                    TP         --                                                   --                   --                tes ad
  273   CNS, DA~2~ antagonist                             FN        TP                                    TP         --                                                   --                   --                islet ad; mam ac; pit ad
  213   CNS, remaining, carbonic anhydrase inhibitor      FN        TP[^a^](#tfn1){ref-type="table-fn"}   TP         --                                                   --                   --                UGT pap
  278   CVS, α~1~ antagonist                              FN        TP                                    TP         br; li; kid; hrt                                     --                   --                adr bpha; mam ac
  259   GI, proton pump inhibitor                         FN        TP                                    TP         --                                                   stom                 --                stom tu; stom SCC; li ad
  215   HM, dual 5-reductase inhibitor                    FN        TP                                    TP         --                                                   --                   --                tes ad
  224   HM, dual 5-reductase inhibitor                    FN        TP                                    TP         --                                                   --                   --                thyr ad
  221   HM, estrogen agonist                              FN        TP                                    TP         --                                                   --                   --                pit ad
  281   HM, estrogen agonist                              FN        TP                                    TP         --                                                   --                   --                li ad; mam ca
  254   HM, GnRH agonist                                  FN        TP                                    TP         --                                                   --                   --                adr bpha; adr mpha; islet ad; tes ad; pit ad; pit ca
  286   HM, GnRH agonist                                  FN        TP                                    TP         --                                                   --                   --                pit ad; pit ca
  257   HM, progestogen--estrogen contraceptive           FN        TP                                    TP         adr; li                                              --                   --                pit ad; mam ad; mam ac
  214   HM, progesterone antagonist, birth cont           FN        TP                                    TP         li                                                   --                   --                li ad; ut ac; mam ac
  241   HM, remaining, aromatase inhibitor                FN        TP                                    TP         --                                                   li                   --                ova gca; UGT pap
  201   HM, selective estrogen modulator                  FN        TP                                    TP         --                                                   --                   --                kid ad; kid ac; ova ad
  202   MB, fibrate                                       FN        TP                                    TP         --                                                   --                   --                tes tu; adr bpha; li ac
  211   MB, fibrate                                       FN        TP                                    TP         li; kid; hrt; adr; tes                               --                   --                pan ad; stom tu; li ad; li ac
  267   MB, HMG-CoA reductase inhibitor                   FN        TP                                    TP         --                                                   --                   --                thyr ad; li ac
  258   MB, remaining, inhib. growth hormone              FN        TP[^a^](#tfn1){ref-type="table-fn"}   TP         --                                                   --                   --                sk sar; ut ac
  228   RS, β~2~ agonist                                  FN        TP                                    TP         --                                                   pan                  --                thyr ad; thyr ac; ova leio; mam ac
  280   RS, β~2~ agonist                                  FN        TP                                    TP         --                                                   --                   --                ova leio
  288   RS, β~2~ agonist                                  FN        TP                                    TP         lu; hrt                                              hrt                  --                ova leio; pit ad; pit ac
  199   RS, β~2~ agonist                                  FN        TP                                    TP         li                                                   --                   --                thyr ad
  227   RS, corticosteroid                                FN        TP                                    TP         --                                                   --                   --                islet tu; adr bpha; skin sar
  158   AB, remaining, bactericidal                       FP        NT                                    FP         li; spl; kid; thyr                                   --                   stom; ut; stom    --
  157   CNS, SSRI                                         FP        TN                                    TN         --                                                   li                   li                --
  159   CVS, α~1~ agonist                                 FP        TN                                    TN         --                                                   --                   mam               --
  145   CVS, α~2~ agonist                                 FP        TN                                    TN         --                                                   --                   thy               --
  149   CVS, α~2~ agonist                                 FP        TN                                    TN         --                                                   --                   islet             --
  156   CVS, angiotensin II antagonist                    FP        TN                                    TN         --                                                   --                   kid               --
  162   CVS, angiotensin II antagonist                    FP        TN                                    TN         --                                                   kid                  kid               --
  147   CVS, β antagonist                                 FP        TN                                    TN         --                                                   adr                  thyr              --
  148   CVS, β antagonist/α~1~ blocker                    FP        TN                                    TN         li                                                   --                   li                --
  151   MB, antidiabetic, remaining, SGLT-2 inhibitor     FP        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   kid                  kid               --
  160   MB, remaining, 3 β-hydroxysteroid dehydrogenase   FP        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   adr                  adr               --
  154   RS, histamine H1 antagonist                       FP        TN                                    TN         --                                                   --                   mam               --
  155   RS, histamine H1 antagonist                       FP        TN                                    TN         li                                                   li                   pan               --
  153   UB, remaining xanthine oxidase inhibitor          FP        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   thyr              --
  144   CVS, α~1~ antagonist                              FP        TP                                    TP         --                                                   --                   mam               --
  161   CVS, α~1~ antagonist and 5-HT~1A~                 FP        TN                                    TP         --                                                   --                   bm                --
  150   IS, immunosuppressive                             FP        TP                                    TP         --                                                   --                   ln                --
  152   IS, immunosuppressive, mTOR inhibitor             FP        TP                                    TP         --                                                   stom; thyr           stom              --
  146   MB, HMG-CoA reductase inhibitor                   FP        TP                                    TP         --                                                   --                   li                --
  2     AF, remaining, benzimidazole                      TN        NT                                    TN         --                                                   --                   --                --
  108   AI, COX2 inhibitor                                TN        TN                                    TN         --                                                   --                   --                --
  72    AI, COX2 inhibitor                                TN        TN                                    TN         --                                                   --                   --                --
  44    AI, NSAID                                         TN        TN                                    TN         kid                                                  --                   --                --
  45    AI, NSAID                                         TN        TN                                    TN         --                                                   --                   --                --
  50    AI, NSAID                                         TN        TN                                    TN         kid; spl                                             --                   --                --
  64    AI, NSAID                                         TN        TN                                    TN         --                                                   --                   --                --
  74    AI, NSAID                                         TN        TN                                    TN         --                                                   --                   --                --
  83    AI, NSAID                                         TN        TN                                    TN         li; kid                                              --                   --                --
  91    AI, NSAID                                         TN        TN                                    TN         hrt; adr; kid                                        --                   --                --
  124   AI, NSAID                                         TN        TN                                    TN         --                                                   --                   --                --
  129   AI, NSAID                                         TN        TN                                    TN         --                                                   --                   --                --
  71    AI, NSAID,                                        TN        TN                                    TN         --                                                   --                   --                --
  7     AI, remaining                                     TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         li                                                   --                   --                --
  122   AI, remaining, cytokine modulator                 TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  73    AM, remaining, antimalarial                       TN        NT                                    TN         --                                                   --                   --                --
  97    AM, remaining, antiparasite                       TN        NT                                    TN         --                                                   --                   --                --
  123   AV,                                               TN        NT                                    TN         --                                                   --                   --                --
  135   AV, herpes genitalis                              TN        NT                                    TN         --                                                   --                   --                --
  60    AV, immunostimulant                               TN        NT                                    TN         li; kid; adr                                         --                   --                --
  104   AV, nucleoside inhibitor                          TN        NT                                    TN         --                                                   --                   --                --
  18    AV, protease inhibitor                            TN        NT                                    TN         --                                                   --                   --                --
  55    AV, viral DNA polymerase inhibitor                TN        NT                                    TN         --                                                   --                   --                --
  3     BM, bisphosphonate                                TN        TN                                    TN         --                                                   --                   --                --
  33    BM, bisphosphonate                                TN        TN                                    TN         --                                                   --                   --                --
  87    BM, bisphosphonate,                               TN        TN                                    TN         thyr; parath                                         bo                   --                --
  28    BM, remaining, calcium-mimetic                    TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  4     CNS, 5-HT~1b/d~ agonist                           TN        TN                                    TN         --                                                   thyr; li             --                --
  107   CNS, 5-HT~1b/d~ agonist,                          TN        TN                                    TN         --                                                   --                   --                --
  95    CNS, 5-HT~3~ antagonist                           TN        TN                                    TN         --                                                   --                   --                --
  24    CNS, antiepileptic, Na-channel blocker            TN        TN                                    TN         --                                                   li                   --                --
  49    CNS, antiepileptic, Na-channel blocker            TN        TN                                    TN         --                                                   --                   --                --
  65    CNS, antiepileptic, Na-channel blocker            TN        TN                                    TN         --                                                   li                   --                --
  66    CNS, antiepileptic, Na-channel blocker            TN        TN                                    TN         --                                                   li                   --                --
  5     CNS, benzodiazepine                               TN        TN                                    TN         --                                                   --                   --                --
  142   CNS, benzodiazepine-like hypnotic                 TN        TN                                    TN         --                                                   --                   --                --
  143   CNS, benzodiazepine-like hypnotic                 TN        TN                                    TN         spl; li; kid; tes; hrt; pit                          li                   --                --
  84    CNS, opioid, μ-agonist                            TN        TN                                    TN         --                                                   --                   --                --
  132   CNS, opioid, μ-agonist, anticholinergic           TN        TN                                    TN         --                                                   --                   --                --
  85    CNS, opioid, μ-antagonist                         TN        TN                                    TN         --                                                   --                   --                --
  86    CNS, opioid, μ-antagonist                         TN        TN                                    TN         --                                                   --                   --                --
  75    CNS, opioid, remaining, κ agonist                 TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  22    CNS, remaining 5-HT, 5-HT~1~-agonist              TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  56    CNS, remaining, acetylcholinesterase inhib        TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   sgl                  --                --
  96    CNS, remaining, AMPA glutamate antagonist         TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  106   CNS, remaining, cannabinoid antagonist            TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  20    CNS, remaining, DA-NA uptake inhibitor            TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         li; adr; thyr                                        li                   --                --
  118   CNS, remaining, GABA-enhancer                     TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  138   CNS, remaining, GABA-metab. inhib.                TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  81    CNS, remaining, MAO-A inhibitor                   TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         lu; kid; thyr; tes; ova                              --                   --                --
  102   CNS, remaining, MAO-B inhibitor                   TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   li                   --                --
  136   CNS, remaining, nicotine agonist                  TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  137   CNS, SNRI                                         TN        TN                                    TN         --                                                   --                   --                --
  103   CNS, SNRI                                         TN        TN                                    TN         --                                                   --                   --                --
  29    CNS, SSRI                                         TN        TN                                    TN         --                                                   --                   --                --
  54    CNS, SSRI                                         TN        TN                                    TN         --                                                   --                   --                --
  112   CNS, SSRI                                         TN        TN                                    TN         kid                                                  li                   --                --
  88    CNS, SSRI, 5-HT antagonist                        TN        TN                                    TN         --                                                   --                   --                --
  15    CVS, ACE inhibitor                                TN        TN                                    TN         --                                                   --                   --                --
  69    CVS, ACE inhibitor                                TN        TN                                    TN         --                                                   --                   --                --
  117   CVS, ACE inhibitor                                TN        TN                                    TN         kid                                                  kid                  --                --
  13    CVS, angiotensin II antagonist                    TN        TN                                    TN         --                                                   --                   --                --
  40    CVS, angiotensin II antagonist                    TN        TN                                    TN         --                                                   --                   --                --
  23    CVS, angiotensin II antagonist                    TN        TN                                    TN         --                                                   kid                  --                --
  10    CVS, anticoagulant                                TN        TN                                    TN         --                                                   --                   --                --
  14    CVS, β antagonist                                 TN        TN                                    TN         --                                                   --                   --                --
  16    CVS, β antagonist                                 TN        TN                                    TN         --                                                   --                   --                --
  17    CVS, β antagonist                                 TN        TN                                    TN         hrt; li                                              --                   --                --
  25    CVS, β antagonist                                 TN        TN                                    TN         pit; lu; hrt; spl; kid; adr; tes; ova; br            --                   --                --
  26    CVS, β antagonist                                 TN        TN                                    TN         --                                                   --                   --                --
  126   CVS, β antagonist                                 TN        TN                                    TN         --                                                   --                   --                --
  127   CVS, β antagonist                                 TN        TN                                    TN         --                                                   --                   --                --
  9     CVS, calcium antagonist                           TN        TN                                    TN         hrt; kid                                             adr                  --                --
  90    CVS, calcium antagonist                           TN        TN                                    TN         spl; kid; ova; hrt; li; adr; br                      --                   --                --
  92    CVS, calcium antagonist                           TN        TN                                    TN         --                                                   --                   --                --
  93    CVS, calcium antagonist                           TN        TN                                    TN         --                                                   --                   --                --
  38    CVS, class 1C antiarrhythmic                      TN        TN                                    TN         thyr; li                                             --                   --                --
  53    CVS, class 1C antiarrhythmic                      TN        TN                                    TN         hrt; li                                              --                   --                --
  6     CVS, endothelin antagonist                        TN        TN                                    TN         --                                                   li; int; adr; mam    nose; bm          --
  115   CVS, endothelin antagonist                        TN        TN                                    TN         --                                                   --                   --                --
  105   CVS, imidazoline agonist                          TN        TN                                    TN         adr; tes                                             --                   --                --
  98    CVS, loop diuretic                                TN        NC                                    TN         --                                                   --                   --                --
  100   CVS, Na-channel block                             TN        TN                                    TN         --                                                   --                   --                --
  101   CVS, Na-channel block                             TN        TN                                    TN         --                                                   li                   --                --
  77    CVS, PDE3 inhibitor                               TN        TN                                    TN         adr                                                  --                   --                --
  99    CVS, platelet aggregation inhibitor               TN        NC                                    TN         --                                                   li; thyr             --                --
  63    CVS, remaining, 5-HT~2~ antagonist                TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         spl; li; kid; hrt; pan; br; thy; adr                 --                   --                --
  141   CVS, remaining, β~1~ partial agonist              TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  36    CVS, remaining, hemostatic                        TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  89    CVS, remaining, Nitr/K^+^ ATP agonist             TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  113   CVS, remaining, PDE~5~ inhibitor                  TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   li; thyr             --                --
  78    CVS, remaining, vasodilator                       TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   hrt                  --                --
  110   CVS, vasopressin-2 agonist                        TN        TN                                    TN         --                                                   --                   --                --
  131   CVS, vasopressin-2 agonist                        TN        TN                                    TN         --                                                   --                   --                --
  121   GI, 5-HT~4~ agonist                               TN        TN                                    TN         --                                                   --                   --                --
  48    GI, histamine H~2~ antagonist                     TN        TN                                    TN         br; hrt; kid; tes; li; ova                           --                   --                --
  94    GI, histamine H~2~ antagonist                     TN        TN                                    TN         li; kid                                              --                   --                --
  119   GI, remaining, anti-osteoporose agent             TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  32    GI, remaining, Fe-chelator                        TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  70    GI, remaining, opioid, μ-agonist                  TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  30    GI, remaining, phosphate binder                   TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  80    GI, remaining, synthetisch prostaglandin          TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         adr; li                                              --                   --                --
  8     IS, remaining                                     TN        NC                                    TN         --                                                   --                   --                --
  76    MB, antidiabetic, α-glucosidase inhib.            TN        TN                                    TN         --                                                   --                   --                --
  68    MB, antidiabetic, DPP~4~ inhibitor                TN        TN                                    TN         --                                                   thyr; li             --                --
  111   MB, antidiabetic, DPP~4~ inhibitor                TN        TN                                    TN         --                                                   --                   --                --
  114   MB, antidiabetic, DPP~4~ inhibitor                TN        TN                                    TN         --                                                   --                   --                --
  139   MB, antidiabetic, DPP~4~ inhibitor                TN        TN                                    TN         --                                                   --                   --                --
  58    MB, antidiabetic, remaining, SU derivative        TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  130   MB, remaining, aldose reductase inhibitor         TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  43    MB, remaining, hypertriglyceridemia               TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  57    MB, remaining, lipid replacement                  TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  1     MB, remaining, nicotinic acid derived             TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  61    RS, anticholinergic                               TN        TN                                    TN         --                                                   --                   --                --
  128   RS, anticholinergic                               TN        TN                                    TN         --                                                   --                   --                --
  11    RS, histamine H~1~ antagonist                     TN        TN                                    TN         --                                                   --                   --                --
  12    RS, histamine H~1~ antagonist                     TN        TN                                    TN         li; lu; hrt; kid; tes                                li                   --                --
  67    RS, histamine H~1~ antagonist                     TN        TN                                    TN         --                                                   li                   --                --
  82    RS, remaining, leukotriene receptor antagonist    TN        TN                                    TN         --                                                   --                   --                --
  116   RS, remaining, mast cell stabilizer               TN        TN                                    TN         --                                                   --                   --                --
  51    UB, anticholinergic                               TN        TN                                    TN         --                                                   --                   --                --
  125   UB, anticholinergic and calcium antagonist        TN        TN                                    TN         thyr; adr; ova; li                                   --                   --                --
  79    UB, remaining, oral β~3~ agonist                  TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   li                   --                --
  62    ZZ, remaining, CFTR potentiator                   TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  39    ZZ, remaining, prostaglandin E2                   TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  109   ZZ, remaining, protein kinase C-beta inhibitor    TN        TN[^a^](#tfn1){ref-type="table-fn"}   TN         --                                                   --                   --                --
  59    CNS, DA2-antagonist/5-HT antagonist               TN        TP                                    TP         --                                                   --                   --                --
  19    CVS, α~1~ antagonist                              TN        TP                                    TP         kid; br; tes                                         --                   --                --
  34    CVS, α~1~ antagonist                              TN        TP                                    TP         --                                                   --                   --                --
  133   CVS, α~1~ antagonist                              TN        TP                                    TP         --                                                   --                   --                --
  41    GI, proton pump inhibitor                         TN        TP                                    TP         --                                                   --                   --                --
  21    HM, GnRH agonist                                  TN        TP                                    TP         --                                                   --                   --                --
  42    HM, progestogen--estrogen contraceptive           TN        TP                                    TP         pit; thyr                                            --                   --                --
  120   IS, immunosuppressive                             TN        TP                                    TP         --                                                   --                   --                --
  140   IS, immunosuppressive                             TN        TP                                    TP         --                                                   --                   --                --
  47    IS, immunosuppressive, mTOR inhibitor             TN        TP                                    TP         --                                                   thyr                 --                --
  52    IS, immunosuppressive, S1P antagonist             TN        TP                                    TP         --                                                   --                   --                --
  134   MB, antidiabetic, remaining, PPAR-γ               TN        TP[^a^](#tfn1){ref-type="table-fn"}   TP         hrt; li                                              li                   --                --
  46    MB, fibrate                                       TN        TP                                    TP         --                                                   --                   --                --
  27    MB, HMG-CoA reductase inhibitor                   TN        TP                                    TP         --                                                   --                   --                --
  35    CNS, SSRI                                         TN        TN                                    TN         --                                                   --                   --                --
  37    CVS, ACE inhibitor                                TN        TN                                    TN         --                                                   --                   --                --
  31    UB, anticholinergic                               TN        TN                                    TN         --                                                   --                   --                --
  184   RS, remaining, antifibrotic                       TP        NC                                    TN         --                                                   adr                  adr               li ad; ut ac
  164   AI, NSAID                                         TP        TN                                    TN         --                                                   --                   kid; UGT          adr bpha
  181   CNS, 5-HT~1b/d~ agonist                           TP        TN                                    TN         kid                                                  --                   epi; tes          thyr ad; pit ad; thy bthym
  176   CNS, 5-HT~3~ antagonist                           TP        TN                                    TN         --                                                   --                   --                li ad; li ac
  183   CNS, antiepileptic, Na-channel blocker            TP        TN                                    TN         kid; adr                                             li                   kid               li ac
  174   CVS, ACE inhibitor                                TP        TN                                    TN         thyr                                                 --                   kid               pit ad; br ac; mes lip; pit ac
  186   CVS, ACE inhibitor                                TP        TN                                    TN         --                                                   kid                  kid               ln bhaem
  167   CVS, α~2~ agonist, ocular                         TP        TN                                    TN         --                                                   int                  int               pan ac; thyr ad; mam ad
  165   CVS, calcium antagonist                           TP        TN                                    TN         li                                                   li                   ln; thyr          thyr ad
  172   CVS, calcium antagonist                           TP        TN                                    TN         --                                                   --                   col               mam fad; adr bpha; tes ad; pit ad; mam ac; pit ca
  182   AF, conazole derivative                           TP        NT                                    TP         li; kid; spl; br; ova; thyr                          --                   thyr              tes tu; br astr; skin mel; mam ac
  171   AV, guanosine analog                              TP        NT                                    TP         --                                                   pit                  tes               mam ac; skin sar
  189   AV, protease inhibitor                            TP        NT                                    TP         --                                                   thyr                 li; kid           adr bpha
  185   CNS, 5-HT~2~ antagonist                           TP        NC                                    TP         li                                                   thyr; mam            mam               thyr ad; mam ac
  163   CNS, DA~2~-antagonist, benzamide                  TP        TP                                    TP         --                                                   --                   mam               pan ad; pan ac; adr bpha; mam ca; pit ca
  188   CNS, DA~2~-antagonist, DA3 antagonist             TP        TP                                    TP         li                                                   --                   lu                mam ca
  177   CNS, remaining, electron transporter              TP        TP[^a^](#tfn1){ref-type="table-fn"}   TP         --                                                   --                   stom              SCC and basal ca
  192   CVS, α~1~ antagonist                              TP        TP                                    TP         --                                                   li; vag              li; mam           thyr ad; thyr ac
  193   CVS, α~1~ antagonist                              TP        TP                                    TP         --                                                   --                   mam               mam ad; hsyst leu
  169   CVS, remaining, hydrazinophthalazine              TP        TP[^a^](#tfn1){ref-type="table-fn"}   TP         --                                                   pit                  thyr              thyr ad; thyr ac
  178   GI, proton pump inhibitor                         TP        TP                                    TP         li; li; lu; stom                                     li; stom; stom       stom              tes ad; tes ad
  187   GI, proton pump inhibitor                         TP        TP                                    TP         li; kid; stom; thyr; hrt; spl                        li; stom; thyr       stom              adr bpha; tes ad; stom SCP; stom SCC; hsyst leu; pit ad
  175   HM, GnRH agonist                                  TP        TP                                    TP         --                                                   --                   tes               pit ad
  180   HM, GnRH agonist                                  TP        TP                                    TP         br                                                   pit                  pit               pit ad
  166   HM, remaining, antiandrogen                       TP        TP                                    TP         tes; adr                                             li; ova; adr; thyr   tes; ova          te ad; thyr ad; ut ac
  179   HM, selective estrogen modulator                  TP        TP                                    TP         --                                                   --                   ova               kid ac; ova ad
  190   MB, HMG-CoA reductase inhibitor                   TP        TP                                    TP         --                                                   li                   li; stom          ut polyp
  173   MB, HMG-CoA reductase inhibitor                   TP        TP                                    TP         thyr                                                 --                   stom              stom SCP; thyr ac; thyr ad
  191   RS, β~2~ agonist                                  TP        TP                                    TP         --                                                   --                   nose              ova leio; pit ad
  168   RS, corticosteroid                                TP        TP                                    TP         --                                                   --                   mam               mam fad; li ac; br astr; li ad
  170   RS, corticosteroid                                TP        TP                                    TP         many; tes; br; hrt; kid; pit; li                     li                   pan; ln           pan ad; pan ac; bo most; li ad; li ac; li ac; mam ad; mam ac

*^a^Decision on category is based on this single case*.

Step 1: Categorization Based on Histopathology {#S4-3}
----------------------------------------------

We have categorized all compounds on the basis of histopathology findings in chronic studies and their relation to tumor findings in the 2-year studies, similar, but not identical, to the criteria in the work of Sistare et al. ([@B16]). The following four categories were identified: Compounds that were negative for histopathological findings considered to be putative preneoplastic in the subchronic study and in the carcinogenicity study were considered true negatives (TNs). Compounds inducing hypertrophy only in subchronic studies were scored as negative.Compounds that were positive for histopathology findings considered to be putative preneoplastic in the subchronic study, but negative for carcinogenicity, were classified as false positives (FPs).Compounds that were positive for both the presence of treatment-related putative preneoplastic histopathological lesions in the subchronic study and the presence of treatment-related benign and/or malignant tumors in the carcinogenicity study were considered true positives (TPs).Compounds that were negative for histopathology findings in the subchronic study, but positive for carcinogenicity, were considered false negatives (FNs).

Step 2: Categorization Based on Pharmacology {#S4-4}
--------------------------------------------

For each pharmacological class, we have listed all compounds and the outcomes of the subchronic study and the carcinogenicity study. We have counted the number of compounds in a pharmacological class and the number of compounds inducing carcinogenicity. A class of compounds was called positive, when 75% of the compounds were associated with tumor induction. These classes are listed in Table [3](#T3){ref-type="table"}.A class of compounds was called negative, when 75% of the compounds were not associated with tumor induction. These classes are listed in Table [4](#T4){ref-type="table"}.A class of compounds was called with mixed outcome, when more than 25%, but less than 75%, of the compounds were associated with tumor induction. These classes are listed in Table [5](#T5){ref-type="table"}.

After considering the mode of action (also based on publicly available literature) leading to induction of tumors, we made an evaluation of the probability that the pharmacology would be the main mode of action causing the carcinogenicity. We have discussed this and added to the tables as the proposed final categorization.

Results {#S5}
=======

A total of 366 pharmaceuticals have been evaluated in the present study, of which 289 met the criteria described in Section "[Materials and Methods](#S2){ref-type="sec"}" for defining valid pairs of rat subchronic (3 and/or 6-month) and 2-year carcinogenicity studies.

Genotoxicity Evaluation {#S5-1}
-----------------------

In our dataset, 21 compounds were assessed as positive or inconclusive with respect to genotoxicity. To give a detailed description is not relevant, since this assessment is conducted initially during the assessment for marketing authorization. After discussions with the sponsor, and before making a decision about the authorization, it was agreed that the genotoxicity findings do not influence the risk for patients. We have therefore decided not to give any weight to these data. None of those compounds is intended to be given to patients with a life-threatening disease, in which case a serious benefit would be judged to outweigh the genotoxicity risk as specified in ICH S1A ([@B2]).

Histopathological Classification {#S5-2}
--------------------------------

### True Negative Compounds {#S5-2-1}

One hundred forty-three (50% of the total) pharmaceuticals that did not induce putative preneoplastic lesions in the subchronic (3- and/or 6-month) study also did not cause treatment-related tumors in the carcinogenicity study (Table [1](#T1){ref-type="table"}, third column). Ninety-nine of these 143 compounds (69%) did neither exhibit any effect on organ weight nor induce cellular hypertrophy in any organ (Table [1](#T1){ref-type="table"}).

Ninety-one of the 143 TN compounds (31% of the total) demonstrated a greater weight of one or more organs, such as liver (*n* = 16); kidneys (*n* = 17); heart (*n* = 11); adrenals (*n* = 10); spleen, ovaries, and brain (*n* = 5); testes (*n* = 7); thyroid (*n* = 6); pituitary and lungs (*n* = 3), or incidentally (*n* = 1) other organs, either or not in combination with cellular hypertrophy (2 substances in liver and 1 substance in kidneys). Twenty-six pharmaceuticals showed cellular hypertrophy in the liver (*n* = 13), thyroid (*n* = 5), adrenals (*n* = 2), and incidentally in the kidneys, mammary glands, bone, salivary glands, or intestines.

Cellular hypertrophy was mainly observed in the liver (*n* = 17), in four cases accompanied by greater liver weight, but not accompanied by the development of benign or malignant hepatocellular tumors.

### False Negative Compounds {#S5-2-2}

Ninety-six (33% of the total) substances did not exhibit putative preneoplastic lesions in the subchronic study, whereas treatment-related benign and/or malignant tumors developed in the carcinogenicity study.

Fifty-two of these 96 compounds (54%) induced benign tumors in a single organ (39) or in multiple organs (13), mainly testes (Leydig cell adenomas), adrenals (pheochromocytomas), pancreas (acinar cell adenomas), thyroid (follicular cell adenomas), pituitary (pars distalis adenomas), and liver (hepatocellular adenomas). Incidental benign tumors were seen in mammary gland, skin, ovaries, urogenital tract, and spleen.

Thirty-five of the 96 compounds (36%) induced benign and malignant tumors in the same organ, mainly liver, thyroid, testes, mammary gland, and pancreas (9%), or in multiple organs (27%).

Nine of the 96 compounds (9%) induced malignant tumors only in a single or multiple organs. These malignant tumors comprised skin sarcomas; adenocarcinomas of the uterus, a localized lymphoma; adenocarcinomas in the kidneys; and leukemia.

Seventy-seven of the 96 compounds (80%) caused tumors that frequently occur spontaneously in rats of the age examined and most of them are not considered relevant for humans.

### False Positive Compounds {#S5-2-3}

Of the 50 compounds that induced putative preneoplastic (hyperplastic) histopathological lesions in the subchronic study, 19 of these (38%) failed to induce treatment-related tumors in the carcinogenicity study.

For these FP compounds, the site of histopathological evidence (cellular hyperplasia) of risk for rat neoplasia was the mammary glands, kidneys, and liver (three compounds each); thyroid and pancreas (two compounds each); and adrenals, stomach, uterus, lymph nodes, thymus, and bone marrow (one compound each).

### True Positive Compounds {#S5-2-4}

Thirty-one substances (11% of the total number) induced putative preneoplastic (hyperplastic) histopathological changes in the subchronic study and treatment-related neoplasms in the carcinogenicity study. In only 13 out of these 31 compounds (42%), the hyperplastic lesion and the tumor developed in the same organ, whereas for the other 18 compounds (58%), the hyperplastic lesions observed in the subchronic study did not develop in the same organ as the tumor in the carcinogenicity study.

Four compounds caused mammary gland hyperplasia in the subchronic study and mammary gland adenomas or carcinomas in the carcinogenicity study. One compound caused mammary gland hyperplasia without the development of mammary gland tumors. This compound induced follicular cell adenomas and carcinomas in the 24-month study but no follicular hyperplasia in the thyroid in the subchronic study. Six substances induced mammary gland (fibro)adenomas and/or adenocarcinomas in the mammary gland without mammary gland hyperplasia in the subchronic study.

Pharmacological Analysis of the Carcinogenic Response {#S5-3}
-----------------------------------------------------

The 289 human pharmaceuticals in the dataset were distributed over therapeutic areas as indicated above (Table [1](#T1){ref-type="table"}, fourth column). Most of the therapeutic areas are divided over several pharmacological classes, and all compounds are distributed through these classes. However, the compounds are anonymized (see Table [1](#T1){ref-type="table"}) due to intellectual-property reasons. A similar approach was followed as for the previous paper on the PhRMA--FDA--JPMA dataset (PFJ dataset) ([@B26]).

### CNS Drugs {#S5-3-1}

#### DA~2~ Agonists \[1\], Refers to the Class in Tables [3](#T3){ref-type="table"}--[5](#T5){ref-type="table"} {#S5-3-1-1}

All four (*245, 265, 270*, and *274*) were found to induce tumors in the sexual organs. For three compounds (*245, 270*, and *274*), Leydig cell adenomas were observed, while for the fourth compound (*265*), uterine carcinomas have been described. For one compound (*274*), skin fibromas were observed too, while for another (*265*), a decrease in spontaneous pituitary adenomas was seen. The dopaminergic DA~2~ agonists are associated with an increase of luteinizing hormone, and the fact that all four compounds induced either testis tumors or uterus tumors confirms the association. In the PFJ dataset ([@B26]), only two compounds were included, with one showing the same tumor profile. Based upon the literature ([@B30]), we could find support for a pharmacodynamic relationship and so we categorized this class as TP.

#### DA~2~ Antagonists \[2\] {#S5-3-1-2}

Three out of four (*59, 163, 188*, and *273*) showed mammary gland adenocarcinomas (two TP and one FN). For one compound, this was the only type of tumor observed (*188*). A second compound (*273*) induced in addition pancreatic acinar cell adenomas and pituitary adenomas. The third compound (*163*) induced adrenal pheochromocytomas, in addition to mammary gland carcinomas. In a 3-month study, mammary hyperplasia was observed for this compound making it a TP. The fourth compound (*59*) was a TN. It is well known that administration of dopaminergic DA~2~ antagonists is associated with an increase in prolactin, resulting in mammary adenocarcinoma in rodents. Based on this pharmacological effect, we categorized this class as TP.

#### 5HT~1b/d~ Agonists \[43\] {#S5-3-1-3}

Four triptanes (*4, 107, 181*, and *277*) showed a rather mixed response. Two compounds (*4* and *107*) did not induce either tumors or hyperplastic responses after 6 months (TN). Two other compounds induced a variety of tumors, one (*277*) with benign pheochromocytomas and Leydig cell adenomas (FN), while with the other (*181*), thyroid follicular cell adenomas and thymomas were observed. However, with the latter compound, Leydig cell hyperplasia was observed at 6 months (TP). Effects on thyroid and testis (Leydig cell hyperplasia and adenoma) are likely be related to liver enzyme induction. In both cases, these effects cannot be related to the direct pharmacodynamic action, which is in agreement with the absence of proliferative effects ([@B31]). A general category of TN is given to this class of compounds.

#### 5HT~3~ Antagonists \[44\] {#S5-3-1-4}

5HT~3~ antagonists (*95* and *176*) have an inhibitory effect on the growth of HT29 cells ([@B32]). Two 5HT~3~ antagonists showed different responses, one (*95*) was TN, while the other (*176*) induced liver adenocarcinomas. As this is unrelated to its pharmacology, the class was categorized as TN.

#### Serotonin and Noradrenaline Reuptake Inhibitors (SNRI) \[47\] {#S5-3-1-5}

Four SNRIs (*137, 203, 250*, and *276*) are included with two (*137* and *103*) as TN, while the other two compounds (*250* and *276*) as FNs showed thyroid adenomas or testicular adenomas, respectively. As these tumors were not associated with primary pharmacology, this class was categorized as TN.

##### μ-Opioid Antagonists \[26\] {#S5-3-1-5-1}

Two are included (*85* and *86*), both TN, and we categorized the class in this way.

##### CNS, Na^+^ Channel Blockers \[46\] {#S5-3-1-5-2}

From six antiepileptics sharing the property of being sodium channel blockers (*24, 49, 65, 66, 183*, and *239*), four are TNs, one compound (*183*) showed liver hyperplasia at 6 months and hepatocellular adenocarcinomas after 2 years (TP). The sixth compound (*239*) showed only adrenal pheochromocytomas after 2 years (FN), which are not relevant for humans. The class is categorized as TN.

##### Selective Serotonin Reuptake Inhibitors \[27\] {#S5-3-1-5-3}

Seven compounds (*29, 35, 54, 112, 157, 262*, and *88*) are included. Five were TNs, with one of them (*112*) showing hepatic hypertrophy, but no hyperplasia, at 6 months. The sixth compound (*262*) induced lymphoreticulum cell tumors (FN), while the seventh (*157*) only showed liver hyperplasia (FP). There is no direct relation with pharmacology, and the relevance for humans is estimated to be negligible. Therefore, selective serotonin reuptake inhibitors (SSRIs) are categorized as TN.

##### μ-Opioid Agonists \[42\] {#S5-3-1-5-4}

Of the three μ-opioid agonists, two (*84* and *132*) are TN, whereas one (*205*) compound showed testis tumors and leukemia (at a non-matching dose). As opiates are not associated with proliferative action, this group was categorized as TN.

##### Benzodiazepine(-Like) Compounds \[45\] {#S5-3-1-5-5}

Three real benzodiazepines and two benzodiazepine-receptor agonists are in this class. Three (*5, 142*, and *143*) are TN. One benzodiazepine (*204*) showed treatment-related thymus lymphomas, thyroid follicular cell adenomas, and uterus schwannomas, especially at high dosages, while another (*248*) showed only thyroid follicular cell adenomas. The latter compound also induced an increase in thyroid weight at 6 months. As these effects were associated with induction of liver metabolism rather than attributed to the primary pharmacology, this class was categorized as TN.

##### 5HT~2~ Antagonists \[16\] {#S5-3-1-5-6}

Two compounds (*185* and *220*) are included. Compound *185* induced mammary gland hyperplasia after 3--6 months, and mammary gland adenocarcinomas and thyroid follicular cell adenomas after 2 years (TP). Compound *220* induced only liver adenomas and no effects at 6 months. There are signals that 5HT~2~ antagonists induce an increase in prolactin, which might be responsible for the association with mammary gland tumors. This has also been discussed with the PFJ dataset ([@B26]). However, this relation between 5HT~2~-receptor blockade and prolactin is not without discussion, and in this case, compound 185 might have also anti-DA~2~ affinity. Because of this uncertainty with respect to the pharmacology, we did not apply a category based upon pharmacology for this class (NC).

##### Remaining 5HT Compounds {#S5-3-1-5-7}

One compound (*22*), a 5HT~1~ agonist was TN. We maintained for the 5HT~1~ agonist the TN category.

##### Remaining Opioid Compounds {#S5-3-1-5-8}

One κ-agonist (*75*) is a TN, which is what we categorized it too.

##### Remaining CNS Compounds {#S5-3-1-5-9}

Seventeen compounds with a large variety of pharmacological targets remained. Nine TNs are a nicotine agonist (*136*), an acetylcholinesterase inhibitor (*56*), a GABA-enhancer (*118*), a GABA-metabolism inhibitor (*138*), a dopamine--noradrenaline reuptake inhibitor (*20*), a monoamine oxidase inhibitor A (MAO-A) (*81*), a MAO-B inhibitor (*102*), an AMPA glutamate antagonist (*96*), and a cannabinoid antagonist (*106*). Several FNs were also present. An α~2~δ agonist of the L-calcium channel (*230*) induced pancreatic acinar cell adenomas and acinar cell adenocarcinomas, and Leydig cell adenomas in males and uterine endometrial polyps in females ([@B33]). A direct pharmacological explanation could not be found in relation to this receptor ([@B34]). Therefore, we maintained a category FN. A melatonin receptor agonist (*197*) induced hepatocellular adenomas and carcinomas, and we gave a TN categorization because of the absence of an association with melatonin receptor stimulation. A COMT inhibitor (*217*) was associated with an increase in kidney tubular adenomas and carcinomas. We maintained category FN, as the kidney effect is likely to be an off-target effect (i.e., not related to pharmacology). An NMDA antagonist (*223*) induced Leydig cell tumors. However, NMDA are usually negative ([@B26]) and therefore were assigned a TN category. A nootropic drug (*261*) was associated with adrenal pheochromocytomas, but categorized as TN, as these tumors are not relevant to humans (see below). A tetracyclic antidepressant (*251*) induced liver adenomas and thyroid follicular cell adenomas based upon induction of metabolism, and also mammary gland tumors, and therefore, we categorized this compound as FN, as there was obvious pharmacological explanation for the latter tumor. A carbonic anhydrase inhibitor (*213*) induced urinary bladder papillomas. These compounds are known to be associated with crystallization in rat urinary bladder, and we applied a category TP for this compound. An electron transporter (*177*) is labeled as TP inducing forestomach hyperplasia in 6-month studies and forestomach squamous cell and basal cell carcinomas in the 2-year study.

Several CNS compounds were associated with adrenal pheochromocytoma, i.e., the DA~2~ antagonist *163*, the NA-channel blocker *23*9, and the nootropic drug *261*. Pheochromocytoma (a tumor developing from the chromaffin cells, which are the sites of synthesis and storage of catecholamines) is the most common neoplasia of the adrenal medulla in rodents. Pheochromocytomas are frequently found in a background of diffuse medullary hyperplasia. Compounds producing this feedback interference include lactose and sugar alcohols such as lactitol and Ca^2+^. High doses of low digestibility carbohydrates, such as mannitol, sorbitol, xylitol, and lactitol, have been reported to increase the absorption and urinary excretion of Ca^2+^ as well as the incidence of all types of proliferative lesions in the adrenal medulla. Hypercalcemia is known to increase catecholamine synthesis. Other compounds that might act *via* altered Ca^2+^ homeostasis and progressive nephrocalcinoses in aging rats include the retinoids. Vitamin D is the most potent *in vivo* stimulus, yet identified for chromaffin cell proliferation in the adrenal medulla. Vitamin D~3~ resulted in a fourfold to fivefold increase in bromodexoyuridine (BrdU) labeling ([@B35]) in the adrenal medulla (focal hyperplasia), leading to pheochromocytomas. In the PFJ dataset, we identified four vitamin D-analogs, all associated with adrenal pheochromocytoma ([@B26]).

### Cardiovascular Drugs {#S5-3-2}

#### ACE Inhibitors \[33\] {#S5-3-2-1}

Eleven angiotensin-converting enzyme inhibitors showed a variety of classifications. Four (*15, 37, 69*, and *117*) are TN. Two (*174* and *186*) are TP based on kidney hyperplasia at 6 months, and for one compound (*174*), pituitary gland adenocarcinomas and mesentery lipomas at 2 years, while for the other compound (*186*), benign hemangiomas were observed in the lymph node. Five compounds (*208, 266, 271, 285*, and *233*) are FN with kidney adenomas in compound *271*, mammary fibroadenomas in compound *285*, Leydig cell tumors in compound *208*, thyroid follicular cell adenomas with compound *266*, and thyroid follicular cell adenomas and endometrial polyps with compound *233*. Van der Laan et al. ([@B26]) mentioned seven negative compounds. The kidney as the target organ of compound *271* suggests a pharmacological effect that might be related to kidney hyperplasia (juxtaglomerular hyperplasia), which was seen with compounds *174* and *186*, as well as with angiotensin II antagonists ([@B26]). Mammary gland fibroadenomas, as seen with compound *285*, are the most common spontaneous tumors in female rats in almost all the routinely used rat strains with incidences of up to 70% in carcinogenicity studies. Fibroadenomas do not progress to malignancy and are not considered to be relevant for humans, whereas mammary gland adenocarcinomas in rats may be more relevant ([@B35], [@B36]). It is important to consider that the windows of mammary gland susceptibility or mammary gland sensitivity are missed when exposure starts in adult nulliparous rodents as is routinely the case in bioassays with pharmaceuticals. The tumors induced by *208* and *266* are likely to be associated with induction of liver metabolic enzymes. The variety of tumors seen with compound *174* is complex. We have categorized the ACE inhibitors as TN in accordance with Van der Laan et al. ([@B26]) overruling all other categories for individual compounds.

#### Ca Antagonists \[14\] {#S5-3-2-2}

Twelve Ca antagonists are included in this dataset. Four are TN (*9, 90, 92*, and *93*). Two (*165* and *172*) are TP, the first with lymph node hyperplasia at 6 months and thyroid follicular cell adenomas after 2 years, and the other showed colon hyperplasia of the muscularis mucosa at 6 months and after 2 years Leydig cell adenomas in the testis, mammary gland fibroadenomas, adrenal pheochromocytomas, and pituitary adenomas and carcinomas. Six others compounds (*200, 235, 237, 240, 256*, and *247*) are FN. Two compounds (*235* and *237*) induced Leydig cell tumors, one induced thyroid follicular cell adenomas (*256*), and one compound (*240*) was associated with pituitary gland adenomas and mammary gland fibroadenomas. Compound *200* induced uterine polyps, while compound *247* induced uterine polyps and oral mucosa squamous cell carcinomas. Calcium antagonists, especially dihydropyridines, are not associated with tumor induction ([@B37]). Eight out of 12 compounds in our dataset are associated with the induction of tumors. Two compounds (*165* and *256*) induced thyroid tumors only, and two (*235* and *237*) only induced testis tumors. Two compounds (*172* and *240*) induced mammary fibroadenomas and pituitary tumors. Compound *247* induced uterine polyps (as did compound *200*) and specifically gingival squamous cell carcinoma. The latter phenomenon is reported for mibefradil ([@B38]), as being due to the oral intake as diet mixture, and not directly related to the pharmacological effect. Van der Laan et al. ([@B26]) classified calcium antagonists as negative, in accordance with absence of induction of cancer in humans ([@B39]). We, therefore, categorized all Ca antagonists as TN, taking into account these considerations.

#### Angiotensin II Receptor Antagonists \[21\] {#S5-3-2-3}

Five compounds (*13, 40, 156, 23*, and *162*) were included. Three compounds (*13, 23*, and *40*) are TN, and two (*156* and *162*) showed juxtoglomerular hyperplasia at 6 months (FP). The induction of juxtaglomerular hyperplasia does not predict further development to kidney tumors, which confirms the findings of Van der Laan et al. ([@B26]), with a slightly different sample set (only two compounds *overlap*). We categorized the class as TN.

#### Adrenergic α~1~ Antagonists \[34\] {#S5-3-2-4}

Eight adrenergic α~1~ antagonists (*19, 34, 133, 144, 192, 193, 278*, and *161*) showed different target organs, with three TN (*19, 34*, and *133*). Three compounds showed mammary gland hyperplasia (*144, 192*, and *193*) and two (*193* and *278*) mammary gland tumors. Two compounds (*192* and *193*) are TP with mammary gland hyperplasia at 6 months and mammary gland adenomas and mononuclear cell leukemia after 2 years. Two (*144* and *161*) are FP, with mammary gland acinar hyperplasia at 6 months for one (*144*) and bone marrow hyperplasia at 6 months for the other (*161*). One FN (*278*) showed after 2 years mammary gland adenocarcinomas and adrenal phaechromocytomas. A direct pharmacological explanation for this connection to the mammary system is unknown at this time. In addition, a connection between α~1~ antagonism and mammary tumor formation is also unknown. A choice for the final classification TP is based on the effects on the mammalian gland, both after 6 months and 2 years for several compounds, despite the fact that we have no clear molecular mechanism. Further research is, therefore, important to study this possible association of α~1~ antagonism and mammary tumor formation.

#### Adrenergic α~1~ Agonists \[35\] {#S5-3-3-5}

Two compounds are included; one (*249*) is FN with only Leydig cell adenomas (related to enhanced liver metabolism) at 2 years, while the other (*159*) was FP with mammary gland acinar hyperplasia at 6 months but no tumors at 2 years. TN was chosen for the final categorization.

#### Adrenergic α~2~ Agonists \[36\] {#S5-3-3-6}

Three compounds (*145, 149*, and *167*) are included, of which one (*145*) is a TN. Compound *149* is FP with hyperplasia of the islets of Langerhans in the pancreas, while compound *167* is TP with small intestines hyperplasia at 6 months and pancreas acinar adenocarcinomas, thyroid follicular cell adenomas, and mammary gland adenomas after 2 years. Three adrenergic α~2~ agonists, therefore, showed variable effects. The islet cell hyperplasia seen with compound *149* might be related to the pancreatic adenocarcinoma seen with compound *167*. A pharmacological target in the pancreas for this class is well known to be inhibitory, e.g., inhibiting insulin secretion. Other compounds in this class have been mentioned in the literature as negative ([@B23], [@B26], [@B40]), and therefore, this group is categorized as TN.

#### Adrenergic β-Antagonists \[25\] {#S5-3-3-7}

Thirteen β-blockers (*14, 16, 17, 25, 26, 126, 127, 147, 148, 203, 219, 243*, and *255*) are included, with seven categorized as TN. Two FP (*147* and *148*) showed thyroid follicular cell hyperplasia or hepatocellular hyperplasia but no tumors. Of the four FN, compound *201* showed hepatocellular hepatomas, compound *219* showed forestomach squamous cell papillomas, compound *243* showed pituitary gland tumors, and compound *255* showed spleen vascular neoplasia. The carcinogenicity potential of β-blockers has been a debate from their early existence, especially with respect to pronethalol ([@B41]).The tumors found were heterogeneous and therefore probably not related to pharmacology. Snyder and Green ([@B23]) also mentioned a low incidence of compounds associated with tumors for this class (2 out of 10). This class was therefore categorized as TN overruling the FN compounds.

#### Anticoagulants \[37\] {#S5-3-3-8}

Two anticoagulants (*10* and *289*) showed slightly different outcomes. The tumor outcome of compound *289* was in fact not statistically relevant but was decided to be a safety signal. However, pancreatic acinar adenomas/carcinomas are usually not relevant for humans. Therefore, we applied a category TN.

#### Imidazoline Agonists \[38\] {#S5-3-3-9}

Two compounds are included (*105* and *252*): one is TN, while the other is FN with adrenal phaechromocytomas and hind limb tumors after 2 years. The adrenal tumors seen with compound *252* might be reflected by a greater adrenal weight for compound *105*, although this might be speculative. The human relevance is low anyway. Therefore, it was decided to categorize these as TN.

#### CVS, Na-Channel Blockers \[39\] {#S5-3-3-10}

Of the three Na-channel blockers used in cardiac treatment (*100, 101*, and *272*), two were TN, compound *227* showed thyroid and Leydig cell adenomas, as well as adrenal pheochromocytomas. As these tumors are more related to drug metabolism, and not pharmacology, we categorized this class as TN.

#### Loop Diuretics \[16\] {#S5-3-3-11}

Three of the four (*98, 229, 253*, and *284*) compounds are FN with compound *284* causing kidney carcinomas, compound *229* causing thyroid follicular cell carcinomas and pituitary gland adenomas, and compound *253* causing uterus adenocarcinomas and Leydig cell adenomas. Compound 284 is a FN, and its target organ suggests a pharmacological profile for the carcinogenesis. The target organs of the other loop diuretics are probably not associated with their pharmacology. As this positive relationship was found for only one compound, we decided to leave the categorization for this class as undecided (NC: non-categorizable based on pharmacological target), with no change of the histopathological categories.

#### Class 1C Channel Blockers \[22\] {#S5-3-3-12}

Two compounds (*38* and *53*), are included, both are TNs, and we also applied this categorization to these based on their pharmacology.

#### Endothelin Antagonists \[23\] {#S5-3-3-13}

Two compounds (*6* and *115*) are included, both are TNs. No proliferative effects are reported for these compounds, and we categorized them as TN based on pharmacology.

#### Vasopressin-2 Agonists \[24\] {#S5-3-3-14}

Two compounds (*110* and *131*) are included and both were TN. No proliferative effects are reported for these compounds, and we categorized them as TN based on pharmacology.

#### Platelet Aggregation Inhibitors \[40\] {#S5-3-3-15}

Two compounds (*99* and *282*) are included. One (*99*) was TN. The other (*282*) showed a variety of tumors, such as thyroid follicular cell adenomas, adrenal pheochromocytomas, hepatocellular adenomas, and endocrine-related tumors such as uterine adenocarcinomas, ovarian adenomas, and mammary gland adenomas. Two platelet aggregation inhibitors had a different tumor response; the first was TN, whereas the other compound was FN because of a dopaminergic action as a secondary pharmacological effect ([@B42]). These compounds were not categorized related to pharmacology (NC).

#### Phosphodiesterase 3 Inhibitors \[41\] {#S5-3-3-16}

One compound (*77*) was TN, while with the other (*209*), adrenal pheochromocytomas were observed. Therefore, we decided to categorize the class as TN.

#### Remaining CVS Compounds {#S5-3-3-17}

Eleven compounds with a variety on pharmacological targets remained to be categorized. A 5HT~2~ antagonist (*63*) is TN, as is a β~1~-partial agonist (*141*). Five other TNs are a nitrate agonist (*89*), a phosphodiesterase-5 inhibitor (*113*), a sodium-channel inhibitor, a hemostatic compound (*36*), and a vasodilator (nitric oxide agonist) (*78*). All compounds were maintained in the TN category. A hydrazine (*169*) is TP with thyroid follicular cell hyperplasia after 6 months and thyroid follicular cell adenomas and carcinomas after 2 years. Because of the thyroid hyperplasia (without any liver signal) after 6 months, we maintained the TP category in this case, although a relation with pharmacology needs to be substantiated. Four compounds are FN, i.e., a DA~1~/α~1~ agonist (*232*) that induced pancreatic acinar cell adenoma, an imidazole PDE inhibitor (*216*) that was associated with adrenal pheochromocytomas, a quinolone vasodilator (*225*), and a renin inhibitor (*198*) that was associated with colon adenoma and carcinoma. However, the colon is unlikely to be a pharmacological target, as Kochi et al. ([@B43]) described an antagonistic effect for this relation. Therefore, we decided to give a TN category to this class.

### Gastrointestinal System {#S5-3-3}

#### Proton Pump Inhibitors \[12\] {#S5-3-3-1}

Four compounds (*41, 178, 187*, and *259*) are included, with one TN. One TP (*187*) showed stomach hyperplasia after 3 months, and monocytic cell leukemia, adrenal pheochromocytomas, pituitary adenomas, Leydig cell adenomas, and squamous cell carcinomas in the forestomach. Another TP (*178*) showed stomach hyperplasia at 6 months and Leydig cell adenomas at 2 years. The third compound (*259*) was associated with hepatocellular adenomas and squamous cell carcinomas in the stomach. The fourth compound was TN. The stomach hyperplasia and squamous cell carcinoma are clearly related to the pharmacology of this class. Therefore, we decided that this class should be categorized as TP, overruling the TN case.

#### 5HT~4~ Agonists \[18\] {#S5-3-3-2}

From the three compounds (*121, 269*, and *212*), one compound (*121*) is a TN, while the other two are FN with tumors in the 2-year studies. Compound *269* showed Leydig cell adenomas and pituitary adenomas, while compound *212* showed thyroid follicular cell adenomas, mammary gland fibroadenomas, pancreatic acinar cell adenomas, adrenal pheochromocytomas, hepatocellular adenomas, and pituitary adenomas. The GI 5HT~4~ agonists are likely to be associated with indirect metabolic effects on thyroid hormones (*269*) or testosterone (*212*). However, this can be debated for compound *269*, but a direct pharmacological explanation is not known. We categorized all these compounds, therefore, as TN.

#### Histamine H~2~ Antagonists \[49\] {#S5-3-3-3}

From the four compounds, two (*48* and *94*) are TN. The other two (*210* and *275*) are FN, with *275* associated with an increased number of skin fibromas, and the compound *210* with Leydig cell adenomas. Histamine H~2~ antagonists are used as gastric acid secretion inhibitors. Inhibition of gastric secretion might be associated with long-term induction of gastric carcinoids as associated with their pharmacological action. None of the compounds in this dataset showed this effect. Therefore, these were categorized as TNs, although in the previous paper, the H~2~ antagonists belonged to the positive class.

#### Gastrointestinal, Remaining Compounds {#S5-3-3-4}

Five compounds remained in this class, and four were categorized as TN, i.e., a synthetic prostaglandin (*80*), a phosphate binder (*30*), an imaging/anti-osteoporose agent (119), and a Fe-chelator (*32*). A sugar alcohol (compound *238*) is associated with Leydig cell adenomas (FN). As this is a rather unspecific effect, the compound was categorized as a TN.

### Hormonal System {#S5-3-4}

#### GnRH Agonist \[3\] {#S5-3-4-1}

From the five compounds (*21, 175, 180, 254*, and *286*), one is TN (*21*) while two are TP (*175, 180*), one with pituitary hyperplasia (*180*) after 3 months and pituitary adenomas after 2 years, and the other showed Leydig cell hyperplasia after 6 months and pituitary adenomas after 2 years. Two compounds (*254* and *286*) are FN, with no hyperplastic effects after 6 months, but both associated with pituitary adenomas and carcinomas after 2 years. One of these compounds (*254*) showed in addition Leydig cell adenomas and pancreatic islet cell adenomas, and adrenal benign and malignant pheochromocytomas. The relation between pharmacology of GnRH agonists and the pituitary tumors observed for four compounds is clear, as the target organ is the pituitary ([@B44]). Only one compound (*21*) is TN, but we categorize all as TP based upon the similar pharmacology as the other members of the class.

#### Estrogen Agonist \[4\] {#S5-3-4-2}

Two compounds (*221* and *281*) are included; one compound (*221*) with pituitary gland adenomas, and the other (*281*) with mammary gland carcinomas and hepatocellular adenomas. For the estrogen agonists, the identity of the target organ supports a pharmacological relationship. Estrogen agonists are important as potential human-relevant carcinogens based upon IARC evaluations ([@B45]), and we categorized this class, therefore, as TP.

#### Selective Estrogen Receptor Modulators \[5\] {#S5-3-4-3}

Two compounds (179 and 201) have a similar tumor profile, i.e., kidney adenocarcinomas and ovary adenomas. Only one (179) showed ovary hyperplasia after 6 months making it a TP, while the other (201) was an FN. We categorized this class as TP.

#### Dual 5-Reductase Inhibitors \[6\] {#S5-3-4-4}

Two compounds (215 and 224) are included, and these are FN. One compound induced Leydig cell adenomas, while the other induced only thyroid follicular cell adenomas. Because of their hormonal action, we categorized these compounds as TP, although the possibility that the tumors might be the consequence of just the induction of liver metabolism cannot be discounted.

#### Progestogen--Estrogen Combinations \[7\] {#S5-3-4-5}

From the two combinations (*42* and *257*), one (*42*) is a TN and the other is a FN (*257*), with mammary gland adenocarcinomas and pituitary adenomas after 2 years. A pharmacological effect on the basis of estrogenic activity is considered to be likely, and therefore, we applied a TP category.

#### Hormones, Remaining Compounds {#S5-3-4-6}

An antiandrogen (*166*) is a TP, with Leydig cell hyperplasia and ovary hyperplasia observed at a 3- or 6-month study. Leydig cell adenomas and thyroid follicular cell adenomas and uterus adenocarcinomas were seen after 2 years. An aromatase inhibitor (*241*) is FN, with urinary bladder papillomas and ovary benign stromal cell tumors after 2 years.

For all pharmacological classes associated with sexual hormones, we conclude that such a relationship is likely to exist between pharmacological action and the induction of tumors, such as for the dual 5-reductase inhibitors (*215* and *224*), and the progestogen-containing combinations (*42, 214*, and *257*). Therefore, we categorized all of these compounds as TP.

### Immunological System {#S5-3-5}

#### Immunosuppressives \[29\] {#S5-3-5-1}

Six immunosuppressive compounds (*120, 140, 150, 47, 152*, and *52*) are all negative. Four compounds are TN and two FP. One of the FPs, compound *150*, showed lymph node hyperplasia at 6 months, and compound *152* showed stomach hyperplasia at 6 months. The fact that all compounds are negative is remarkable, as the immunosuppressive action is a well-known risk factor for the induction of cancer. Bugelski et al. ([@B46]) showed that around 50% of immunosuppressive compounds were associated with some type of cancer, probably based upon the spontaneous presence of oncogenic viruses. The absence of a carcinogenic effect for these immunosuppressive compounds could be explained by an absence of oncogenic viruses during these studies. It is known that immunosuppression is a real risk factor for human carcinogenicity. From that point of view, the ICH-S1 Expert Working Group indicated that compounds with an immunosuppressive risk could warrant a waiver in the future. Cyclosporin is also a class 1A (IARC) proven human carcinogen. Therefore, we decided to categorize the class of immunosuppressives as TP, despite the lack of tumors in these studies.

#### Immunomodulators \[52\] {#S5-3-5-2}

Two compounds are included. Compound *8* is a TN, while compound *242* is a FN with pituitary adenomas noted at 2 years. Categorization of this class based on pharmacology remains uncertain. Therefore, we maintained the histopathological categorization for these compounds.

### Metabolic System {#S5-3-6}

#### Antidiabetics, α-Glycosidase Inhibitors \[50\] {#S5-3-6-1}

Two compounds (*76, 194*) are included; one (*76*) is TN. The other has been studied in relation to glucose inclusion in the diet and as a pair-fed study. The study with glucose resulted in Leydig cell adenomas after 2 years, whereas without glucose, kidney tumors were observed. A final pair-fed study did not reveal any treatment-related increase in tumors. As the target of α-glycosidase inhibitors is rather the intestine than the kidney, we concluded that this should be considered an off-target effect. We categorized this class, therefore, as TN.

#### Dipeptidyl Peptidase Inhibitors (DPP4 Inhibitors) \[28\] {#S5-3-6-2}

Four DPP4 inhibitors (*68, 111, 114*, and *139*) were all TN. Apparently, the inhibition of the breakdown of GLP-1 is only low and does not lead to the induction of thyroid C-cell tumors, as is known from GLP-1 agonists such as liraglutide ([@B47]). We categorized this class as TN.

#### PPAR-α-Agonists (Fibrates) \[8\] {#S5-3-6-3}

Three compounds are included (*46, 202*, and *211*). One is TN (*46*). Two are FN, with both compounds inducing hepatocellular carcinomas, accompanied with pancreas acinar cell adenomas and forestomach squamous cell carcinomas for compound *211*. Compounds *46* and *202* showed Leydig cell adenomas and adrenal pheochromocytomas. Fibrates are known to target the liver, but the pancreas can also be listed as a target organ based on their class properties related to peroxisome proliferation ([@B48]). Because of the pharmacological profile, the histopathological categorization TN and FN, respectively, was considered to be overruled by TP for this class.

#### HMG-CoA Reductase Inhibitors (Statins) \[9\] {#S5-3-6-4}

Five compounds (*27, 146, 190, 173*, and *267*) are included. One (27) is a TN and one (*267*) was a TN in Fisher rats but FN in Sprague-Dawley rats as hepatocellular adenocarcinomas and thyroid follicular cell adenomas were observed in this strain. Compound (*146*) was a FP with hepatocellular hyperplasia at 3 months, while compound (*190*) is a TP with hepatocellular hyperplasia at 3 months (although only hypertrophy was observed in a 6-month study) and uterus endometrial polyps after 2 years. Compound (*173*) induced forestomach hyperplasia after 6 months, and thyroid follicular cell adenomas and carcinomas and forestomach squamous cell papillomas after 2 years. Whether or not all these tumors are related to the pharmacological action of statins is not completely certain, as discussed in Ref. ([@B26]). In fact, the outcome is that statins can be expected to be carcinogenic anyway. Therefore, we categorized the complete class as TP.

#### Remaining Metabolic Compounds {#S5-3-6-5}

Six remaining compounds are included. An antidiabetic sulfonylureum derivative (*58*), a lipid replacement (*57*), a nicotinic acid derivative (*1*), a triglyceride-lowering compound (*43*), a PPAR-gamma agonist (*134*), and an aldose reductase inhibitor (*130*), are all TN. We gave the category TN to all these compounds as no other evidence for a proliferative effect on the basis of receptor stimulation could be found. A 3-betahydroxy derivative (*160*) and an SGLT-2 inhibitor (*151*) are FP, with adrenal gland hyperplasia in the cortex or kidney hyperplasia after 6 months, respectively. Thus far, no SGLT-2 inhibitor was associated with renal effects in rats ([@B49], [@B50]). An inhibitor of growth hormone (*258*) is FN with skin sarcomas and uterus endometrium carcinomas after 2 years.

### Respiratory System {#S5-3-7}

#### Anticholinergics \[30\] {#S5-3-7-1}

Two anticholinergic compound (*61* and *128*) intended to be administered *via* the inhalation route are TN. Therefore, we categorized these compounds as TN based upon their pharmacology.

#### Adrenergic β~2~-Agonists \[10\] {#S5-3-7-2}

Five compounds are included (*191, 199, 228, 280*, and *288*). The most common feature was ovarian leiomyomas as seen for four of the five compounds. For the RS, the association of mesovarian leiomyomas with β~2~-agonist is well described, although one compound (199) showed only thyroid adenoma. Even for recent long-acting β~2~-agonists such as indacaterol and vilanterol ([@B51], [@B52]), these tumors have been observed. A broader disturbance of the gender HM is clear from the mammary adenocarcinoma (*228*) and the effects on the pituitary (*191* and *288*). We categorized this class as TP based on pharmacology.

#### Corticosteroids \[11\] {#S5-3-7-3}

Three compounds are included (*168, 170*, and *227*). Two compounds (*168* and *170*) are TP. Compound *168* showed mammary gland acinar hyperplasia at 6 months, and at 2 years, mammary gland fibromas, brain astrocytomas, and hepatocellular adenomas were observed. Compound *170* showed lymph node hyperplasia and pancreas islet cell hyperplasia at 6 months, and hepatocellular adenomas, pancreas acinar cell adenomas, mammary gland adenomas and adenocarcinomas, and bone osteomas and osteosarcomas were observed in the 2-year study. Compound *227* is a FN and showed pheochromocytomas, pancreatic acinar cell tumors, and skin fibrosarcomas. The relationship between the pharmacology of corticosteroids and the target organs observed is not easy to understand, but the wide distribution of corticosteroid receptors is in accordance with the broad list of organs bearing tumors, suggesting a broad pharmacological perspective. We categorized the corticosteroids as TP.

#### Histamine H~1~ Antagonists \[48\] {#S5-3-7-4}

Seven compounds (*11, 12, 67, 154, 155, 195*, and *207*) are included, with three TN (*11, 12*, and *67*). Two FPs (*154* and *155*) showed mammary gland acinar cell hyperplasia at 3 months, while compound *155* showed islet cell hyperplasia and hepatocellular hypertrophy at 6 months. Only two compounds (*195* and *207*) were associated with tumors (FN). Compound *195* showed pheochromocytomas, and compound *207* showed thyroid follicular cell adenomas, hepatocellular adenomas, and carcinomas. It is likely that these effects are associated with the induction of liver enzymes, based upon the target organs and the presence of pituitary adenomas and carcinomas. In general, the class is categorized as TN.

#### Remaining Respiratory Compounds {#S5-3-7-5}

Compound *184*, an antifibrotic agent, induced adrenal hyperplasia after 6 months, but liver adenoma and uterine adenocarcinoma after 2 years, making it histopathologically a TP. Pharmacologically, it could not be categorized, as no relationship is known to exist between the effects of the two endpoints. The effects are rather unspecific, and therefore, we finally decided to categorize it a TN. Compound 264 is a methylxanthine derivative is a FN with testis tumors and mammary fibroadenoma, rather than unspecific tumors, and therefore, we categorized this as TN. Compound 116 is a TN mast cell stabilizer.

### Antimicrobial Agents {#S5-3-8}

#### Antibiotics, Fluoroquinolones \[13\] {#S5-3-8-1}

Three compounds (*231, 244*, and *263*) are all FN. The first showed renal adenomas and carcinomas, the second showed leukemia, and the third was associated with pancreatic neoplasms. As the primary pharmacology is not directed to a mammalian target, we categorized these compounds as non-mammalian target (NT).

#### Remaining Antibiotics {#S5-3-8-2}

One compound (*158*), a bactericidal agent, is FP with forestomach hyperplasia at 6 and 12 months.

#### Antifungal Agents, Conazole Derivatives \[14\] {#S5-3-8-3}

Three compounds (*182, 226*, and *236*) are included. The first (*182*) is a FN with skin, brain, testis, and mammary gland tumors. Compound *226* showed hepatocellular adenomas, and compound *236* showed a low incidence of soft tissue carcinomas. The classes of triazole antifungals do not have a mammalian target by definition, as discussed above. A specific effect on liver enzyme metabolism is described for related members of the class of antifungals ([@B53]). The first molecular event is not fully clear but might be the binding to a CYP450 subcategory. Conazoles induce hepatic cell proliferation in mice. We have categorized the antifungals as NT.

#### Remaining Antifungals {#S5-3-8-4}

One compound (*2*) is a TN, while another (*279*) is a FN showing hepatocellular adenomas and carcinomas, as well as Leydig cell tumors. We categorized them all as NT.

#### Antimicrobials, Remaining Antimicrobials {#S5-3-5-5}

Two AM are included, an antimalarial drug (*73*) and an antiparasital compound (*97*) (anti-lice). Both compounds are TN. As the primary pharmacology is not directed to a mammalian target, we categorized these compounds as NT.

#### Antivirals \[32\] {#S5-3-8-6}

The antivirals (*18, 55, 60, 104, 123, 135, 171, 189, 218*, and *246*) do not belong to the same class and have different types of therapeutic use and modes of actions. Six compounds, an immunostimulant (*60*), a nucleoside-analog (*104*), a viral DNA polymerase inhibitor (*55*), a protease inhibitor (*18*), a nucleoside combination (*123*), and an anti-herpes compound (*135*), are all TN. Four compounds (*171, 189, 218*, and *246*) showed tumors. As antivirals do not have direct primary pharmacological targets in mammals, as discussed above, the variety of effects might be due to completely different mechanisms of action. For compound *246*, liver induction might have led to increased T3 metabolism, eventually resulting in thyroid tumors. A similar explanation is not possible for compounds *171* and *218*. In these individual cases, the potential human risk of the induction of tumors has been evaluated, and the relevance of these effects is negligible compared to the benefit of clinical treatment.

A CCR5 receptor antagonist (*246*) is FN with thyroid adenomas after 2 years. A guanosine analog (*171*) is FN with mammary gland adenocarcinomas after 2 years. A protease inhibitor (*189*) is TP and showed hepatocellular hyperplasia after 6 months and adrenal pheochromocytomas after 2 years. As none of the antiviral showed a clear connection to a mammalian pharmacological target, we just categorized them as NT.

### Anti-inflammatory Compounds {#S5-3-9}

#### Non-Steroidal Anti-inflammatory Drugs \[19\] {#S5-3-9-1}

Twelve "classical" cyclooxygenase 1/2 inhibitors (*44, 45, 50, 64, 71, 74, 83, 91, 124, 129, 164*, and *260*) are included with 10 being TN. One (*164*) compound is a TP with kidney hyperplasia at 6 months, and after 2 years, adrenal pheochromocytomas and hyperplasia in the urinary bladder were observed. The histopathological changes and tumors induced cannot be directly explained. The adrenal pheochromocytomas are assumed to be not relevant for humans. For another compound (260), it is assumed that induction of CYP450 would lead to an increased testosterone metabolism, which leads *via* a feedback mechanism to Leydig cell adenomas. We have categorized this class as TN.

#### Cyclooxygenase-2-Inhibitors \[31\] {#S5-3-9-2}

Four compounds (*108, 72, 206*, and *222*) are included. Two compounds (*72* and *108*) are TN. The two other compounds (*206* and *222*) are FN with hepatocellular adenomas and carcinomas. One compound (*222*) also showed thyroid follicular cell adenomas. The target organs suggest a relation with the liver-induced metabolism and not to a direct pharmacological response. This supports the negative properties of the NSAID (COX1/2-inhibitor) class, as discussed above. Based on this relationship, we categorized the class as TN.

#### Remaining Anti-inflammatory Compounds {#S5-3-9-3}

Two compounds are included (*7* and *122*), which are both TN, and we categorized them the same.

### Urinary Bladder {#S5-3-10}

#### Anticholinergics \[51\] {#S5-3-10-1}

Six compounds (*31, 51, 125, 268, 283*, and *287*) are included, with three (*31, 51*, and *125*) categorized as TN and three (*268, 283*, and *287*) as FN. Compound *268* was associated with benign uterine polyps and kidney papillomas, compound *283* with kidney sarcomas, and compound *287* with skin sarcomas, all with high dosages or incidental findings. The class was categorized as TN.

#### Remaining Urinary Compounds {#S5-3-10-2}

A xanthine oxidase inhibitor (*153*) is FP with thyroid hyperplasia at 6 months. A β~3~-agonist (*79*) is TN. We have placed both in the category TN.

### Bone Metabolism {#S5-3-11}

#### Bisphosphonates \[20\] {#S5-3-11-1}

Three compounds (*3, 33*, and *87*) are included and shown to be TN. Van der Laan et al. ([@B26]) described a pharmacological explanation for a positive finding, i.e., thyroid c-cell adenoma. This is not, however, confirmed in the present data, and we maintained the TN category.

#### Remaining Compounds Affecting Bone Metabolism {#S5-3-11-2}

An isoflavone derivative (*234*) is a FN with pituitary gland adenomas and hepatocellular adenomas after 2 years. A calcium-mimetic (*28*) is TN. As the tumor targets for compound *234* are rather unspecific, we categorized both as TN.

### Remaining Compounds {#S5-3-12}

Four compounds (*39, 62, 109*, and *196*) remained pharmacologically unclassified. Three were TNs, a prostaglandin E2-analog (*39*), a CFTR potentiator (*62*), and a protein kinase C-beta inhibitor (*109*). A retinoid for topical administration (*196*) is a FN, with adrenal phaechromocytomas and thyroid follicular cell adenomas after 2 years. As the tumor effects are rather unspecific, we assigned a TN category to this compound and maintained the TN for the others.

Discussion and Conclusion {#S6}
=========================

The present retrospective study using data from rat subchronic (3- and/or 6-month) toxicity and 2-year carcinogenicity studies obtained from the non-clinical assessment reports, available at the Medicines Evaluation Board of the Netherlands, was performed to test independently a "weight-of-evidence approach," expressed in the ICH Regulatory Notice Document ([@B54]) that was based on the "whole animal negative predictivity hypothesis" of Reddy et al. ([@B25]) and Sistare et al. ([@B16]). This might strengthen the assumption that the absence of any putative preneoplastic lesion in a subchronic study is associated with a negative outcome of a 2-year carcinogenicity study in rats, and therefore, no further long-term carcinogenicity study is needed. Furthermore, we have evaluated the role of the pharmacological properties in this respect.

In order to build evidence for the possibility of prediction, we used information that is commonly available at the end of Phase II in the development of human pharmaceuticals for designing a 2-year carcinogenicity study, including data on pharmacology and genotoxicity, and data from subchronic toxicity studies in rodents, as was undertaken earlier by Van der Laan et al. ([@B26]).

The dataset that we used has some overlap with the PFJ dataset as used by Van der Laan et al. ([@B26]), and we identified an overlap of 76 compounds. We decided to include these, as the application of more stringent criteria of putative neoplasm (see below) has led to differences in the categorization and to a higher number of FN.

Role of Liver Hypertrophy versus Hyperplasia {#S6-1}
--------------------------------------------

A large number of pharmaceutical compounds induced greater (relative) liver weight, and the question arises about the role of this property in the weight-of-evidence approach. A greater liver weight may result from a wide variety of causes such as hyperplasia (of any of the resident cell types), hypertrophy, inflammation, fibrosis, abnormal storage of metabolism or cleavage products, neoplasia, and congestion ([@B55]--[@B57]). Typically, these changes do not occur in isolation, so in the absence of overt adverse changes such as inflammation, necrosis, or degeneration, it is important to recognize that an increase in liver weight may be induced by hypertrophy, hyperplasia, or a combination of the two ([@B58]). A xenobiotic that induces an increase in liver weight of 150% in a subchronic study might be considered to induce adverse effects in the context of dose setting for longer term studies but would not be considered to be adverse in the context of safety evaluation ([@B59], [@B60]).

In a survey of 139 chemicals used in the agrochemical industry, Carmichael et al. ([@B59]) demonstrated that a relative greater liver weight of ≥150% of control values was correlated with the induction of liver tumors in mice. In a similar review of rat studies, a less statistically significant relationship between liver weight and hepatocarcinogenesis was noted, whereby greater liver weight alone correctly predicted 8 of 11 liver carcinogens (but falsely predicted 26 as positives) and failed to predict 3 TPs ([@B59]).

Our findings demonstrate that treatment-related changes in organ weights, observed in a subchronic study with rats, are most likely non-specific and therefore should not be considered as a risk factor for neoplasia.

The histopathological diagnosis of hypertrophy can have various connotations, including a greater weight of the organ and an increase in the average size of the cells and even enzyme induction (functional hypertrophy). Allen et al. ([@B61]) evaluated the results for 111 chemicals tested by the National Toxicology Program. If they applied hepatocellular necrosis, hepatocellular hypertrophy, hepatocellular cytomegaly, and greater liver weight as predictors for carcinogenicity, greater liver weight appeared to be the most sensitive parameter. However, chemicals that produced liver tumors frequently induced multiple morphological changes. They concluded that the best single predictor of liver cancer in mice was hepatocellular hypertrophy. They found no FNs, but numerous FPs, in their evaluation.

In the present study, 33 compounds with a TN label showed an increase in hepatocellular hypertrophy in the subchronic study that was not accompanied by development of hepatocellular adenomas and/or carcinomas in the carcinogenicity study, whereas in only 7 cases was liver hypertrophy accompanied by the development of hepatocellular adenomas (3) or hepatocellular adenomas and carcinomas (4).

These observations support our starting point to classify hyperthrophy as an adaptive, rather than a putative, preneoplastic lesion. If we had assessed hepatocellular hypertrophy as an indicator for the development of hepatocellular tumors, 33 compounds would have been overpredicted as potential liver carcinogens (FP substances). This confirms that liver hypertrophy observed in a subchronic study is an unreliable predictor of carcinogenicity. This is in agreement with the conclusion from the 3rd International ESTP Expert Workshop ([@B62]) that hepatomegaly as a consequence of hepatocellular hypertrophy without histological or clinical pathological alterations indicative of liver toxicity is an adaptive reaction.

Histopathological Evaluation {#S6-2}
----------------------------

First, the predictivity was evaluated based upon the histopathological characterization.

*The negative predictivity*, the measure of the compounds evaluated that did not show any putative preneoplastic lesion in the subchronic studies and were negative in the carcinogenicity studies, was 60%, whereas the sensitivity, a measure of the subchronic study to predict positive carcinogenicity outcome, was only 24% (Table [2](#T2){ref-type="table"}). In contrast, the specificity, the accuracy of the subchronic study to correctly identify non-carcinogens, was 88%. Based only on the absence of putative preneoplastic lesions in the subchronic study, 56% of the 2-year carcinogenicity studies could have been eliminated at the risk of 96 (33%) FN.

###### 

**Predictivity of the subchronic toxicity study for the carcinogenicity of non-genotoxic pharmaceuticals**.**[^a^](#tfn2){ref-type="table-fn"}**

                                                                                                Carcinogenicity                                    
  -------------------------------------------------------- ------------------------------------ ----------------- ------- --------- --------- ---- -----
  Subchronic tox                                           Positive                             31                19      62        21 (NT)   67   1
                                                           Negative                             96                143     14 (NC)   192       17   204
                                                                                                                                                   
                                                                                                **%**             **%**   **%**                    
                                                                                                                                                   
  False negatives                                          =\[96/(96 + 143 + 31 + 19)\] × 100   33                5       6                        
  Negative predictivity[^b^](#tfn3){ref-type="table-fn"}   =\[143/(143 + 96)\] × 100            60                93      92                       
  Positive predictivity[^c^](#tfn4){ref-type="table-fn"}   =\[31/(31 + 19)\] × 100              62                75      98                       
  Sensitivity[^d^](#tfn5){ref-type="table-fn"}             =\[31/(31 + 96)\] × 100              24                82      80                       
  Specificity[^e^](#tfn6){ref-type="table-fn"}             =\[143/(143 + 19)\] × 100            88                90      99                       

*^a^The subchronic (3-month) study results were used to categorize a compound as true positive (TP), false positive (FP), false negative (FN), and true negative (TN)*.

*^b^Ability to predict non-carcinogens: \[TN/(TN + FN)\] × 100*.

*^c^Ability to predict rat carcinogens: \[TP/(TP + FP)\] × 100*.

*^d^Ability to detect rat carcinogens: \[TP/(TP + FN)\] × 100*.

*^e^Ability to detect non-carcinogens: \[TN/(TN + FP)\] × 100*.

*The positive predictivity* (62%) is the percentage of compounds that showed putative preneoplastic changes in the subchronic study and caused treatment-related tumors in the 24-month carcinogenicity study.

Thirty-one substances were classified as TP. However, for only 13 compounds, the putative preneoplastic lesions developed in the same organs as the tumors. Eighteen compounds induced hyperplastic lesions in another organ than the organ where the tumors occurred. This observation is in agreement with the conclusion of Reddy et al. ([@B25]) that the whole animal approach assumes that preneoplastic changes at any organ will be indicative for an increase in tumor incidence in that organ or in any organ at a distant site. A closer look at the organs (Table S1 in Supplementary Material: compounds 163--193) illustrates the importance of physiological relationships between organs. Several compounds induce their own metabolism in the liver and, as a consequence, enhance the enzymes responsible also for the metabolism of hormones, such as T3 and testosterone/estradiol, lowering their concentration. This decrease in hormone concentration leads to a feedback responses to the pituitary, resulting in enhanced secretion of thyroid-releasing hormone and/gonadotropin-releasing hormone, which in turn may lead to the development of tumors.

False Positive Compounds {#S6-3}
------------------------

Nineteen chemicals induced putative preneoplastic (hyperplastic) histopathological changes in the liver, thyroid, kidneys, mammary glands, pancreas, stomach, adrenals, and incidentally in other organs, whereas no tumors occurred in the carcinogenicity study, neither in the same organ nor in an organ at a distant site. This observation supports the conclusion of Jacobs ([@B24]), based on an evaluation of 60 pharmaceuticals, that various short-term indicators for carcinogenicity, such as hyperplasia, do not always result in tumors in that tissue, although such putative preneoplastic histopathological lesions are generally considered a sign of potential concern for carcinogenicity.

Woutersen et al. ([@B63]) performed a retrospective study and evaluated the subchronic (3 months) studies of 163 non-genotoxic chemicals with the aim to predict the tumor outcome of 24-month rat carcinogenicity studies. In this study, the negative predictivity, a measure to predict a negative carcinogenicity outcome, amounted to 97%, whereas the sensitivity, a measure to predict a positive carcinogenicity outcome, was only 5%. Overall, this study supports the concept that chemicals showing no histopathological risk factors for neoplasia in a subchronic study in rats may be considered non-carcinogenic and do not require further testing in a carcinogenicity study. The findings observed in the present paper with TP and FP compounds are in agreement with the conclusion of Reddy et al. ([@B25]) that more research is needed in order to achieve understanding of the biological links between putative preneoplastic lesions observed in a subchronic study and tumors developing at distant organ sites in the carcinogenicity study. The concept of adverse outcome pathways is helpful in this respect, defining as the first step the molecular event and then subsequent steps leading to the final outcome of tumors in different organs.

False Negative Compounds {#S6-4}
------------------------

Since it is generally accepted that the intention of screening assays should be conservative, it is most important that the number of FNs with respect to human carcinogens should be as low as possible. In the present study, 96 compounds were classified as FN because they did not show putative preneoplastic lesions in the 3- and/or 6-month study but caused treatment-related tumors in the carcinogenicity study. These compounds are of concern with regard to the acceptability of the negative predictivity of the whole animal approach stating that the absence of evidence of putative preneoplastic lesions in all tissues in the 3- and/or 6-month study may serve as a strong negative predictor of tumor outcome in the carcinogenicity study.

When we evaluate these FN substances histopathologically, 77 of the 96 FN substances appeared to induce benign tumors or benign and malignant tumors, which are considered not relevant for the human situation ([@B36]): acinar pancreatic tumors and islet cell neoplasia ([@B36]); pheochromocytomas of the adrenal medulla ([@B64]); forestomach tumors ([@B65], [@B66]); hepatocellular tumors induced by peroxisome proliferators ([@B48], [@B67]--[@B69]); fibroadenomas of the mammary gland ([@B70]); pituitary tumors (adenohypophysis tumors) ([@B71]); Leydig cell (interstitial cell) tumors of the testes ([@B72], [@B73]); thyroid follicular cell tumors ([@B74]--[@B76]); and urinary bladder tumors ([@B75], [@B77]--[@B80]) and uterus tumors (endometrial stromal polyps) ([@B81]). That means that 19 FN substances still remain using this approach.

Impact of Pharmacology {#S6-5}
----------------------

To evaluate further the remaining 19 FN substances, we compared this number with the outcome of an evaluation integrating the pharmacological properties of the compounds. We have tested the hypothesis that a pharmacological explanation, as known for several years ([@B30]), and integrated in the histopathological approach recently ([@B26]), will help to reduce the number of FNs.

To study the role of the pharmacology in relation to histopathology, we have evaluated whether the mode of action is related to a proliferative mechanism or only to non-proliferative mechanisms. We have selected those classes that are clearly related to induction of tumors as positive classes (Table [3](#T3){ref-type="table"}) and classes not related to induction of tumors as negative classes (Table [4](#T4){ref-type="table"}). A series of classes with mixed outcome have been evaluated in relation to literature, and for each pharmacological class, a clear outcome of "positive" or "negative" has been chosen (Table [5](#T5){ref-type="table"}), meaning a high or low percentage of rat carcinogens, respectively. For the remaining individual compounds, we have taken into consideration the specificity of the tumors, i.e., those tumors likely to be associated with a change in metabolism of hormones (thyroid, or testosterone, or calciferol) are not related to a specific pharmacological mechanism. The compounds are, therefore, categorized as TN.

###### 

**Classes with high percentage of rat carcinogens (positive classes)**.

                                           Class                               Total number of compounds   Compounds with tumors   Proposed final category
  ---------------------------------------- ----------------------------------- --------------------------- ----------------------- -------------------------
  **Related to direct pharmacology**                                                                                               
  1                                        CNS, DA~2~ agonists                 4                           4 (100%)                TP
  2                                        CNS, DA~2~ antagonists              4                           3 (75%)                 TP
  3                                        HM, GnRH agonists                   4                           4 (100%)                TP
  4                                        HM, estrogen agonists               2                           2 (100%)                TP
  5                                        HM, selec. estrogen receptor mod.   2                           2 (100%)                TP
  6                                        HM, dual 5-reductase inhibitors     2                           2 (100%)                TP
  7                                        HM, progestogen (combinations)      3                           2 (67%)                 TP
  8                                        MB, HMG-CoA reductase inhibitors    5                           3 (60%)                 TP
  9                                        MB, fibrates                        3                           2 (67%)                 TP
  10                                       RS, adrenergic β~2~ agonists        5                           5 (100%)                TP
  11                                       RS, corticosteroids                 3                           3 (100%)                TP
  12                                       GI, PP inhibitors                   4                           3 (75%)                 TP
  **Not related to direct pharmacology**                                                                                           
  13                                       Antibacterial, fluoroquinolones     3                           3 (100%)                NT
  14                                       Antifungal triazole derivatives     3                           3 (100%)                NT
  15                                       CVS, calcium antagonists            12                          8 (67%)                 TN
  16                                       CVS, loop diuretics                 4                           3 (75%)                 NC
  17                                       CNS, 5HT~2~ antagonists             2                           2 (100%)                NC
  18                                       GI, 5HT~4~ agonist                  3                           2 (67%)                 TN

###### 

**Classes with low percentage of rat carcinogens (negative class)**.

       Class                           Total number of compounds   Compounds with tumors   Proposed final category
  ---- ------------------------------- --------------------------- ----------------------- -------------------------
  19   AI, NSAIDs                      12                          2 (17%)                 TN
  20   BM, bisphosphonates             3                           --                      TN
  21   CVS, angiotensin II antag.      5                           --                      TN
  22   CVS, class 1C antiarrhytmics    2                           --                      TN
  23   CVS, endothelin antagonists     2                           --                      TN
  24   CVS, vasopressin-2 agonists     2                           --                      TN
  25   CVS, adrenergic β-antagonists   13                          3 (21%)                 TN
  26   CNS, μ-opioid antagonists       2                           --                      TN
  27   CNS, SSRIs                      7                           1 (14%)                 TN
  28   MB, DPP4 inhibitors             4                           --                      TN
  29   IS, immunosuppressives          6                           --                      TN
  30   RS, anticholinergics            2                           --                      TN

###### 

**Classes with medium percentage of rat carcinogens (mixed outcome class)**.

       Class                                    Total number of compounds   Compounds with tumors   Proposed final category
  ---- ---------------------------------------- --------------------------- ----------------------- -------------------------
  31   AI, COX-2 inhibitors                     4                           2 (50%)                 TN
  32   Antivirals                               10                          4 (40%)                 NT
  33   CVS, ACE inhibitors                      9                           5 (55%)                 TN
  34   CVS, adrenergic α~1~ antag.              8                           3 (38%)                 TN
  35   CVS, adrenergic α~1~ agonist             2                           1 (50%)                 TN
  36   CVS, adrenergic α~2~ agonist             3                           1 (33%)                 TN
  37   CVS, anticoagulant                       2                           1 (50%)                 TN
  38   CVS, imidazoline agonists                2                           1 (50%)                 TN
  39   CVS, Na-channel blockers                 3                           1 (33%)                 TN
  40   CVS, platelet aggreg. inhib.             2                           1 (50%)                 NC
  41   CVS, PDE~3~ inhibitors                   2                           1 (50%)                 TN
  42   CNS, μ-opioid agonists                   3                           1 (33%)                 TN
  43   CNS, 5HT~1b/d~ agonists                  4                           2 (50%)                 TN
  44   CNS, 5HT~3~ antagonists                  2                           1 (50%)                 TN
  45   CNS, benzodiazepines                     5                           2 (40%)                 TN
  46   CNS, antiepileptic, Na-channel blocker   6                           2 (33%)                 TN
  47   CNS, SNRIs                               4                           2 (50%)                 TN
  48   RS, histamine H~1~ antag.                7                           2 (28%)                 TN
  49   GI, histamine H~2~ antag.                4                           2 (50%)                 TN
  50   MB, α-glycosidase inhibitors             2                           1 (50%)                 TN
  51   UB, anticholinergics                     5                           3 (60%)                 TN
  52   IS, immunomodulators                     2                           1 (50%)                 NC

Based upon pharmacology, combined with a previous histopathological categorization, we have given a final category in a separate column. This final category is applicable only to those classes for which at least two compounds are present in the dataset.

We have separated the compounds without a direct pharmacological effect in mammalian tissue from the other compounds.

Table [3](#T3){ref-type="table"} contains a list of pharmacological classes with a high percentage of rat carcinogens (positive classes). In line with the earlier overview ([@B26]), we can differentiate between carcinogenicity directly related to pharmacology and carcinogenicity not related to pharmacology. Antibiotics, antifungals, and antivirals are developed to act against specific mechanisms in their target organism. Of course, it is possible that off-target effects exist in mammals. Apparently, this is true for the metabolic enzymes in liver. We have chosen, therefore, to give a separate classification to all compounds without a non-mammalian target (NT).

Based upon the identity of the organs bearing tumors (i.e., associated with liver, thyroid, adrenal, and testis), we have put the antibacterials, antifungals, and antivirals in the same category.

The calcium antagonists, the loop diuretics, and the GI 5HT~4~ agonists are in the list of "not related to pharmacology."

Combined Evaluation of Histopathology and Pharmacology {#S6-6}
------------------------------------------------------

In Table [1](#T1){ref-type="table"}, we have incorporated the pharmacology-based categorization in the column labeled as Cat. Ph, by taking the pharmacology as an additional factor (Table [1](#T1){ref-type="table"}, fifth column). In this way, we categorized most of the compounds as TP (if belonging to a positive class) or TN, as explained above.

A combination of the histopathological categorization of the compounds together with the pharmacological categorization of the pharmaceuticals gave the following overall results: Twenty-one pharmaceuticals that do not have a mammalian target (8FN, 1FP, 9TN, and 3TP) are included.Fifty-two of the 96 FN compounds were recategorized as TNs based on pharmacology; 27 were recategorized as TPs; in addition to the 8 without mammalian target, 9 were not recategorized due to an unknown relationship between pharmacology and carcinogenicity.Fourteen FP compounds were recategorized to TN based on pharmacology; five were recategorized as TP. One remained FP, as there is no pharmacological target.One hundred twenty-four TNs remained TN, while 14 were categorized as TP. Five were not categorized (NC).From the 41 TP compounds, 11 were recategorized as TN, while 17 remained TP on the basis of their pharmacology. Two could not be categorized, and three had no mammalian target.Finally, 14 out of 289 (5%) pharmaceuticals evaluated in the present retrospective study have not been recategorized. Nine are FN, and five are TN.After recategorization, based on both histopathology and pharmacology, the number of FN compounds was reduced to only 17 out of 289 (6%). The negative predictivity amounted to 92%; the positive predictivity to 98%, and the sensitivity was 80%, whereas the specificity amounted to 99% (TP: 67; FP: 1; FN: 17; and TN: 204) (see Table [6](#T6){ref-type="table"}).

###### 

**Summarizing table based upon final categorization**.

          Histopathological categories (Table S3 in Supplementary Material)   Pharmacological categories (Table S4 in Supplementary Material)   Final categories (Table [1](#T1){ref-type="table"})   
  ------- ------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------------------------------------------
  TN      143                                                                 192 (47[^a^](#tfn7){ref-type="table-fn"})                         204                                                   No preneoplastic signals in subchronic studies, no pharmacological signals, no carcinogenicity
  TP      31                                                                  62 (5[^a^](#tfn7){ref-type="table-fn"})                           67                                                    Preneoplastic signals in subchronic studies, pharmacological signals, carcinogenicity
  FN      96                                                                                                                                    17                                                    Not conclusive
  FP      19                                                                                                                                    1                                                     
  NT                                                                          21                                                                                                                      
  NC                                                                          14                                                                                                                      
  Total   289                                                                 289                                                               289                                                   

*^a^Single-in-class decisions*.

*NC, non-categorizable based on pharmacological target; NT, non-mammalian target in mammalian tissue; FN, false negative; FP, false positive; TN, true negative; TP, true positive*.

When the FN compounds that gave rise to tumors generally considered not relevant for human risk assessment, and those categorized as TN based on the pharmacological analyses, were moved from the FN category to the TN category, the negative predictivity of the 3- and/or 6-month study for the absence of carcinogenicity (the ability to predict non-carcinogens) amounts to 96% and the specificity (the ability to detect non-carcinogens) to 99% (Table [3](#T3){ref-type="table"}).

The analysis of this paper clearly shows that adding pharmacological properties as an additional factor of potential carcinogenicity gives a good prediction, reducing the number of FN substantially, which has consequences for the risk assessment of these pharmaceuticals.

Conclusion {#S7}
==========

Our results demonstrated that subchronic (3- and/or 6-month) studies, in combination with knowledge of pharmacological properties, could appropriately categorize non-genotoxic pharmaceutical into two categories: (i)unlikely to be carcinogenic in rats if (1) no histopathological risk factor for neoplastic lesions observed in the subchronic study in any tissue, and (2) general absence of systematic, specific carcinogenicity in the pharmacological class.(ii)likely carcinogenic in rats if (1) putative preneoplastic lesions observed in the subchronic study may give rise to a type of tumor in the rat 24-month carcinogenicity study that is irrelevant for humans; therefore, a carcinogenicity study has no additional value; (2) this is confirmed by the results from the pharmacological class.

We should keep in mind that the real focus is on the prediction of carcinogenicity in humans, and we cannot quantify the full translational value of the rodent carcinogenicity study. However, overall, the results of this retrospective study support the whole animal approach as proposed by Reddy et al. ([@B25]) and Sistare et al. ([@B16]), especially with respect to the negative outcome of the subchronic studies as prediction for a negative outcome of a carcinogenicity study. Moreover, the results (predictivity) are consistent with the recent and similar investigation on chemicals ([@B63]). Furthermore, the data show the added value of the pharmacological evaluation of compounds in relation to potential class effects, both in the negative and positive direction. This evaluation strongly enhances the prediction of a possible impact for rodents and eventually for an extrapolation of the carcinogenic risk to humans. The outcome can be used to further prevent conducting unnecessary carcinogenicity studies. For most of the pharmacological mechanisms, it is well known that the non-genotoxic mode of action carries no risk of carcinogenicity for the human situation because of important species-related differences between rodents and humans.

In this way, the pharmacological analysis confirms the approach recently published by Van der Laan et al. ([@B26]) and reflected in the ICH Regulatory Notice Document to incorporate the pharmacological properties in predicting a positive and a negative outcome of a 2-year carcinogenicity study.

A high negative and a high positive predictivity of the carcinogenic potential of a pharmaceutical compound based on the findings in subchronic toxicity studies in rats, combined with knowledge of the pharmacological class, should result in waiving the need for conducting 2-year rat carcinogenicity studies, which will lead to a reduction in the numbers of animals used for scientific purposes and will save time and expense for drug development.

The dataset used for this analysis gives important opportunities for further research. As in addition to rat data, also mouse data are included, we can have a better understanding of the different outcomes between rats and mice, as discussed previously by Van Oosterhout et al. ([@B27]) and Friedrich and Olejniczak ([@B15]). Their reports point to the low regulatory relevance of lifetime mouse studies, and potential reduction of 2-year rat studies as proposed in the ICH RND ([@B54]), should at least be accompanied by measures with respect to 18- or 24-month mouse studies. Further discussion is recommended on the predictive value of the involvement of cytochrome *p* 450ies in the induction of cell proliferation in liver or other organs such as thyroid gland and testis. These and other questions require further analysis of the studies in this database.
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